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ABSTRACT OF THE DISSERTATION
Cerebral Amyloid Angiopathy and Transition Metals in Alzheimer’s Disease
by
Matthew Schrag
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, December 2010
Dr. Wolff M. Kirsch, Chairperson
Alterations in brain metals homeostasis and particularly brain iron overload have
been postulated to play a role in Alzheimer’s disease, contributing to oxidative stress and
neuronal injury; however, the source of this iron is not clear and may be due to metabolic
derangement(s), failed iron clearance mechanisms or exogenous deposition such as
through bleeding. This series of studies was designed to evaluate the extent of metals
dyshomeostasis in the Alzheimer’s disease brain and specifically whether microvascular
bleeding is a major contributor to Alzheimer’s disease-related iron overload. Cerebral
amyloid angiopathy (CAA) is a vascular manifestation of Alzheimer’s disease present to
some degree in up to 95% of Alzheimer’s disease patients. This vasculopathy results in
vascular inflammation and fragility which produces clinically detectable bleeding (by
susceptibility weighted MR imaging) in many Alzheimer’s disease patients. We
analyzed brain iron levels by gold-standard atomic absorption spectrometry in brain
tissue from patients with severe CAA, in those with Alzheimer’s disease without
significant vascular involvement and in aged control tissue. We also observed iron, zinc
and copper in these tissues histologically by novel techniques to qualitatively assess their
association with vascular and perivascular abnormalities. Increased iron in the subset of
Alzheimer’s disease patients with CAA is accompanied by increased levels of heme
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degradation enzymes, heme oxygenase and biliverdin reductase. Finally, because the
mechanism(s) underlying vascular fragility in CAA is unknown, we evaluated the role of
terminal complement on cerebrovascular elements in the setting of CAA. This may
provide mechanistic clues to how the structural stability of arterioles is undermined in
this microangiopathy. If iron overload is a feature of CAA rather than a more general
feature of Alzheimer’s disease, it is possible that chelation therapies will be more
effective for the subset of Alzheimer’s patients with severe vasculopathy. This
information combined with an effective clinical test for CAA has the potential to refine
therapeutic strategies.

xii

CHAPTER ONE
INTRODUCTION

The Clinical Problem of Alzheimer’s Disease
Alzheimer’s disease (AD) was described more than 100 years ago by a 43 year
old neuropathologist named Dr. Alois Alzheimer who recognized the two key
neuropathological markers of this neurodegenerative disease. He described extracellular
plaques of a material we now know to be aggregates of a protein peptide called betaamyloid. He also described an intraneuronal pathology he termed “tangles” which
appeared as intense silver-staining of the axons of certain neurons (Zilka and Novak
2006). This pathology is now understood to result from the hyperphosphorylation of a
cytoskeleton-associated protein called tau which is normally responsible for stabilizing
the microtubules associated with normal neuronal axons. Upon hyperphosphorylation,
this molecule can no longer function normally and aggregates within neurons, becoming
visible as a neurofibrillary tangle. This is associated with destabilization of the axon and
the loss of synaptic connections. These pathologies present in the context of severe
neuronal loss through apoptosis and cortical atrophy leading to the clinical manifestations
of the disease.
Patients affected by Alzheimer’s disease typically present with mild memory
impairments in or after the seventh decade of life although about 5% of cases are
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hereditary (usually with autosomal dominant inheritance) and cause clinical dementia as
early as the fourth or fifth decade of life (and occasionally even earlier). The earliest
phase of the disease falls in a clinical category termed mild cognitive impairment (MCI)
which also affects many individuals with normal age-related memory loss. Patients given
the diagnosis of MCI may progress to outright dementia (at a typical rate of 17% per
year) or remain cognitively stable (Landau 2010). About two-thirds of those who
progress to dementia will ultimately be diagnosed as having Alzheimer’s disease. This
disease affects approximately 14% of adults in the United States over the age of 65 and
up to 40% of octogenarians. The disease initially presents with isolated memory loss, but
the cognitive impairment worsens with time to include word-finding difficulty (or
anomia), visual-spacial dysfunction and ultimately loss of executive function (Samanta
2006). AD is currently believed to be the seventh most common cause of death in the
United States (Alzheimer’s Association 2010). The most common mechanism of death
in patients affected by Alzheimer’s disease is pneumonia precipitated by aspiration
because of the loss of gag reflexes and cognitive protection of the airway (Kahlia 2003).
Average survival after diagnosis is reported to range from 3.1 to 7.6 years (Molsa 1995,
Aguerro-Torres 1999, Helmer 2001, Wolfson 2001, Brookmeyer 2002, Ganguli 2005,
Helzner 2008).
A number of therapeutic options are available, but none has been shown to
reverse or even slow cognitive dysfunction. Acetylcholinesterase inhibitors have been
developed based on the observation that the nucleus basalis of Meynert is severely
affected by Alzheimer’s pathology, leading to a reduction in acetylcholine levels (Cuello
2010). These drugs are reasonably well-tolerated and produce a brief improvement in

2

non-cognitive symptoms of Alzheimer’s disease such as performance of activities of
daily living. N-methyl d-aspartate (NMDA)-receptor antagonists have been used based
on evidence of glutamate-mediated neurotoxicity in AD brain. This therapy is of
comparable effectiveness with acetylcholinesterase inhibitors (Areosa 2005). In many
cases, the most significant medical therapy is treatment for depression. Depression is a
major risk factor for AD, more than doubling the risk in an individual over age 60
(Devandan 1996). In fact, it may be reasonable to see depression in some cases as an
early sign of cognitive dysfunction. As with other therapies for AD, anti-depressants
have not been shown to alter cognitive function as measured by standard tests, but have
shown efficacy for improvements in behavioral disturbances, performance of activities of
daily living and reducing caretaker distress (Lyketsos 2003).

The Research Problem
AD as a research priority is of obvious importance -- this is a disease process that
ranks among the most prolific killers in the United States. A clear understanding of the
etiology and molecular mechanism(s) underlying AD, after over one-hundred years of
intense study, remains elusive. At present a conclusive diagnosis can only be obtained at
autopsy or through brain biopsy, which means the vast majority of dementia patients are
not diagnosed until death (Alzheimer’s Association 2010). These features of the disease
have complicated research efforts. An enormous number of hypotheses have been
presented to explain the etiology and progression of this disorder over the last halfcentury. A number have fallen by the wayside, like the now-rejected hypothesis that
toxicity from aluminum exposure leads to the disease.
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Currently, the leading hypothesis in the field of Alzheimer’s disease research is
the amyloid hypothesis which in its simplest form argues that beta-amyloid deposition is
the initiating event in the progression of Alzheimer’s neurodegeneration and that the
other features of the disease descend from this initial abnormality (Hardy and Higgins
1992). This basic mechanism is nearly indisputably accurate for a number of variants of
Alzheimer’s disease, including the presenilin mutations, mutations in the APP gene and
trisomy 21 (Down’s syndrome) which all result in overproduction of beta-amyloid
peptide. The mechanism is also supported by evidence that beta-amyloid applied to
cultures of neurons or tissue cultures of brain results in hyperphosphorylation of tau and
apoptotic death of neurons – both key additional features of Alzheimer’s disease (Forloni
1993, Schrag 2008). Other data seems to contradict this hypothesis including evidence
that plaques and tangles are not consistently distributed together in AD brain and
vaccination against the beta-amyloid peptide, while successfully clearing plaques from
the brain, was not able to consistently reverse or slow the progression of cognitive
decline (Holmes 2008).
The tau hypothesis argues that abnormal phosphorylation of tau is the central
pathology of Alzheimer’s disease and is based on the observation that decline in
cognitive function correlates far more with the extent of tau pathology than it does with
beta-amyloid pathology. It is not clear whether hyperphosphorylation is due to
overactivity of specific kinases (such as GSK3-beta) or deficient levels or function of key
phosphatases (like tau protein phosphatase), but hyperphosphorylation results in
destabilization of microtubules and loss of typical neuronal morphology (Honson and
Kuret 2008).
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Other hypotheses have suggested chronic hypoperfusion, abnormal microglial
activation or other inflammatory mechanisms, altered calcium homeostasis, oxidative
stress mechanisms etc to explain the pathologic changes associate with AD.
Increasing attention has been paid to the role of redox active transition metals as
potential early players in AD pathogenesis. Free iron, in particular, with its ability to
participate in Fenton chemistry, is thought to occupy a central role in initiating oxidative
injury culminating in neuron loss (Castellani 2004). Additionally iron, zinc and copper
are concentrated within beta-amyloid plaques, a pathological hallmark of AD (Lovell
1998). These observations have prompted intense study of central nervous system iron
chelators in animal models with some degree of success, although preliminary clinical
trials have had mixed results (Crapper-McLaughlin 1992, Squitti 2002, Lannfeldt 2006).
The notion that iron accumulates in the brain as an early feature of AD has both
therapeutic and diagnostic implications. If true, recent advances in MRI techniques,
including iron-sensitive gradient echo-T2* (GRE-T2*) and susceptibility weighted
imaging sequences (SWI), should be able to detect the increased tissue iron (Haacke
2005). This methodology may provide a clinically useful biomarker of AD and a
mechanism for monitoring the efficacy of iron-modulating therapies. More immediately,
the technique enables in vivo evaluation of the iron-accumulation hypothesis in human
beings and a correlation of iron accumulation to the clinical progression of dementia.

Previous Work
A post-mortem analysis of brain tissue from various lobar regions was performed
by atomic absorption spectrometry (Magaki 2007). Samples were obtained from
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cognitively normal elderly brain, early Alzheimer’s disease, and severe Alzheimer’s
disease brain from both frontal lobe and hippocampus. Copper, and non-heme, loosely
bound and total iron were measured. Total and non-heme iron levels were not
significantly altered in the AD cases, while loosely bound iron (isolated from
mitochondria) was increased and copper was decreased. These findings were at odds
with the widely held belief that iron is markedly increased in AD – various review
articles report AD brain iron to be increased by two to five fold (Avramovich-Tirosh
2008, Bush and Tanzi 2008, Molina-Holgado 2007, Huang 2004).
Our group also designed and executed a longitudinal, prospective clinical trial to
evaluate radiologically the correlation of two distinct markers of brain iron with the
progression of dementia using SWI (Kirsch 2009). Regional parenchymal iron
concentration may be semi-quantitatively estimated in vivo using this technique because
iron produces a loss of signal intensity. Additionally, punctate sources of high-iron
concentration produced characteristic small, round hypointensities in some images.
These hypointensities were thought to represent brain microbleeds, and in the setting of
dementia are distributed with a posterior lobar predilection characteristic of CAA. CAA
is comorbid with AD in as many as 95% of AD cases (Jellinger 2007). In this condition
the β-amyloid peptide is deposited along the cerebral and meningeal vasculature in the
walls of small and medium-sized arterioles. Vascular wall infiltration with these proteins
appears to be associated with a structural instability of arterioles accounting for brain
microbleed (BMB) and associated MR signal voids. In vivo evidence of CAA was
limited until the introduction of GRE-T2* weighted MR imaging, which remains the
clinical standard for detection of BMB which often result from CAA (Atlas 1988).
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Though recent reviews of the BMB literature have attempted to codify the interpretation
of these findings, the inconsistency of data sets, the lack of pathological confirmation and
the need for better designed prospective studies to determine their clinical significance
has been emphasized (Cordonnier 2006, 2007, Viswanathan 2006). Detection of BMB is
improved by new, high-resolution, 3D GRE-T2* and SWI. SWI is an advance in T2*
weighted brain MR imaging that enhances contrast from local susceptibility tissue
variations (Haacke 2004, 2005). At 1.5T, the SWI sequence was found to be four fold
more sensitive for detection of traumatic BMB than conventional GRE-T2* and recent
data in MCI subjects indicates again at least a four fold increase in BMB recognition by
SWI compared to conventional GRE-T2* imaging (Haacke 2007, Tong 2003, 2004). To
date, punctate signal voids have been observed in a number of diseases – by far the most
common are hypertension and CAA. Those associated with hypertensive vasculopathy
tend to be localized to basal ganglia, internal capsule, brain stem, and cerebellum,
whereas those associated with CAA are generally smaller with a posterior lobar
predilection (Rosand 2005 and Walker 2004).
Of the fifty patients enrolled in this study with mild cognitive impairment (MCI the earliest clinically detectable stage of cognitive loss), 23 remained cognitively stable
throughout the follow-up period while 27 progressed to dementia. Of the brain-regions
of interest, only the left putamen demonstrated a significant loss of signal intensity in the
cohort that progressed to dementia compared to both the stable MCI population and the
normal control cases. Two or more BMB were observed in ten patients in the study. Of
these ten, nine progressed to dementia while one remained stable at MCI. All nine who
progressed to dementia had a progressive increase in the number of hypointensities, while
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the one stable case did not have an increasing number. These findings indicate that CAA
and microbleeds represent clinically important pathologies and are detectable in
approximately one-third of dementia patients prior to the onset of cognitive loss.
One final study formed the background for this body of work. Longitudinal
serum samples were collected from the patients described in the previous study.
Proteomic analysis of peptides carried on albumin in the serum identified certain peptide
breakdown products of heme degradation enzymes that were markedly elevated in MCI
patients who would ultimately progress to dementia compared to those who remained
stable. In particular, the ratio of biliverdin reductase B-related peptides to heme
oxygenase 1-related peptides was markedly increased in the group that progressed to
dementia. These findings may represent a valuable early biomarker of Alzheimer’s
disease, but they may also indicate abnormal activation of the heme degradation system
in AD.
The findings from these studies provoke an important question: Could the absence
of iron-overload in these cases indicate that iron dysregulation and overload is not
inherently a feature of Alzheimer’s disease, but rather of a comorbidity like CAA which
produces microbleeding? Previous post-mortem tissue analyses of Alzheimer’s disease
brains in our laboratory failed to demonstrate an increase in either total iron concentration
(in any studied region) or non-heme (chelatable) iron (Magaki 2007). Additionally, no
dysregulation of iron regulatory proteins 1 or 2 could be demonstrated in our studies and
no clear metabolic derangement has been consistently reported in the literature (Magaki
2007). However, heme-degradation pathway enzymes are reported to be increased in
both AD brain and in peripheral serum samples from dementia patients (Premkumar
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1995, Mueller 2010). CAA could potentially explain this pattern of findings and account
for the source of pathological iron reported in numerous qualitative studies. While a
wide spectrum of CAA severity is present in AD, at autopsy more than 95% of AD
patients are found to have some degree of CAA pathology. Bleeding below the threshold
of detection for our current MRI techniques has been reported and demonstrated to be
associated with amyloid plaque formation (Cullen 2005). However, in our study, onethird of the dementia cases had detectable hypointensities thought to be CAA-related
bleeding. AD accounts for about two-thirds of all dementia cases, meaning
microbleeding may be a major disease mechanism in as many as half of all AD cases
(Hendrie 1998).

Hypothesis and Aims of Current Studies
We proposed to clarify the degree to which iron is dysregulated in AD and to
identify the source of abnormal iron. Several studies utilizing very different
methodologies were required to answer these questions. We conducted a meta-analytic
review of available literature to determine whether iron is actually increased in AD and to
better understand how the belief that AD is a disease of iron-overload developed.
Effective meta-analysis requires objective inclusion and exclusion criteria, so all studies
encountered were included in the analysis unless there was an objective reason to exclude
them. In particular, results reported from fixed tissue appeared to differ from results
obtained from never-fixed specimens. We felt it was necessary to specifically confirm
the effect of tissue fixation before excluding studies on fixed tissue from the analysis.
Additionally, we extensively searched available literature, including studies in foreign
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languages and studies which were not PubMed indexed. After confirming by metaanalysis that iron was not increased in quality-controlled studies of AD brain, we
analyzed the citation patterns in key literature to better understand how the belief to the
contrary developed.
Subsequently, we evaluated whether microvascular bleeding secondary to CAA
accounts for the increased iron reported by some investigators in AD cases. This was
accomplished by correlating brain iron levels and heme degradation pathway enzyme
levels to the degree of CAA in post-mortem cases. If the hypothesis is true, non-heme
iron measurements should increase in CAA-affected tissue and be associated with
increases in heme-degradation pathway enzymes indicative of tissue exposure to blood.
If iron overload is a feature of CAA rather than a more-general feature of AD, it is
possible that chelation therapies will be more-effective for a subset of Alzheimer’s
patients with severe vasculopathy. Finally, because iron-overload appeared to be due
primarily to microbleeding, we assessed whether hypointense foci in susceptibility
weighted images accurately identified microhemorrhages in CAA tissue and observed the
pathology present in these locations to better understand the mechanism of vascular
degeneration associated with CAA.
The findings of these studies indicate that iron is not globally dysregulated in
Alzheimer’s disease, despite the dogmatic belief to the contrary in the field. When iron
overload is present in a subset of AD brains, it correlates with microbleeding and CAA,
and not with the presence of parenchymal hallmarks of AD. Microbleeding events can be
detected by susceptibility weighted images in vivo which is a reasonable imaging
biomarker of severe CAA. Finally, the mechanism associated with vascular degeneration
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in CAA appears to be associated with the deposition of pro-oxidative copper and iron in
the arteriolar walls and prominent late-complement activation – pathologies which may
be directly associated with beta-amyloid deposition.
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Abstract
Reports that iron, zinc and copper homeostasis are in aberrant homeostasis are
common for various neurodegenerative diseases, particularly for Huntington’s disease,
Parkinson’s disease and Alzheimer’s disease. Manipulating the levels of these elements
in the brain through the application of chelators has been and continues to be tested
therapeutically in clinical trials with mixed results. Much of the data indicating that these
metals are abnormally concentrated in Alzheimer’s disease and Parkinson’s disease brain
tissue was generated through the analysis of post-mortem human tissue which was
archived in formalin. In this study, we evaluate the effect of formalin fixation of brain on
the levels of three important transition metals (iron, copper and zinc) by atomic
absorption spectroscopy. Paired brain specimens were obtained at autopsy for each case;
one was conserved by formalin archival (averaging four years), the other was rapidly
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frozen. Both white and grey matter samples were analyzed and the concentrations of iron
and zinc were found to decrease with fixation. Iron was reduced by 40% (p<0.01), and
zinc by 77% (p<0.0001); copper concentrations increased by 37% (p<0.05) by the paired
T-test. The increase in copper is likely due to contamination from trace copper in the
formalin. These results indicate that transition metal data obtained from fixed tissue may
be heavily distorted and care should be taken in interpreting this data.

Introduction
The measurement of trace metals in human tissue has revealed numerous insights
into both normal physiology and disease. Brain iron concentration increases with age,
reaching a plateau at about age 55 (Hallgren and Sourander 1958). Disturbances in the
levels of various metals including iron in the brain are reported to be associated with
many neurodegenerative disorders, including Huntington’s disease, amyotrophic lateral
sclerosis, Alzheimer’s disease (AD) and Parkinson’s disease (PD). In these diseases, iron
is known to accumulate in the deep grey matter and iron accumulation in the neocortex
has been suggested to contribute to the cognitive dysfunction associated with some of
these diseases. Abnormal accumulation of iron in the AD brain could account for
increased oxidative injury which is an early finding in Alzheimer’s disease and increases
in brain iron have in fact been reported early in this condition mirroring the oxidative
changes (Smith 2010, Nunomura 2001), although several additional studies have failed to
detect any abnormal changes in brain iron in AD compared to age-matched controls at
various stages of the disease (Hallgren and Sourander 1960, Ward and Mason 1987,
Magaki 2007). Additionally, beta-amyloid peptides which aggregate to form senile
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plaques in Alzheimer’s and Parkinson’s diseases, avidly bind to iron, zinc and copper.
When these metals are bound, the toxicity of beta-amyloid is reported to markedly
increase (Rottkamp 2001). Pharmacologically manipulating the levels and/or distribution
of these metals in the brain is becoming a clinical reality for Alzheimer’s disease and
Parkinson’s disease through the use of chelators and metallophores – several of which are
in clinical trials (Crapper McLachlan 1991, Squitti 2003, Lannfelt 2008). Initial results
have been mixed; modest improvement in secondary measures like the performance of
activities of daily living has been reported, but no agent has yet produced an
improvement in cognition.
Reports that iron, zinc and possibly copper are abnormally concentrated in
neocortical brain in Alzheimer’s and that all three metals are deposited in beta-amyloid
plaques were primarily generated from analysis of post-mortem, fixed tissue through
histochemical and radioanalytical techniques (such as particle induced X-ray emission
tomography) (Goodman 1953, Lovell 1998). The reliability of this data set requires that
formalin archival of tissue does not disturb the levels of these transition metals. We
noted that previous reports of iron concentrations from both normal and diseased brains
which utilized fixed specimens appear to report substantially lower concentrations than
studies which use never-fixed specimens analyzed with equivalent techniques (Lovell
1998, Diebel 1996). To evaluate whether this observation represents an artifact
introduced through the fixation technique, we have evaluated paired brain samples taken
from the temporal lobe of Alzheimer’s disease patients to determine whether samples
stored in formalin have equivalent levels of three key transition metals – iron, copper and
zinc.
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Materials and Methods
Post mortem tissue was donated from the Alzheimer’s Disease Research Center
Brain Bank at the University of California, Los Angeles. All patients and/or their
surrogates had consented to tissue donation prior to autopsy. The research protocol was
approved by the Institutional Review Board of Loma Linda University Medical Center
(approval #54174). Both frozen and formalin-archived tissue was collected from the
middle temporal gyrus of four severe Alzheimer’s disease brains. Tissue samples were
isolated with a diamond blade scalpel and titanium and/or nylon forceps (to avoid
contamination) and collected as 30-60 mg specimens of isolated grey or white matter.
From fixed tissue, the surface of tissue blocks was dissected away to remove any tissue
which might have been exposed to iron-containing instruments through the autopsy
procedure.
Tissue was ashed for analysis by standard techniques. Briefly, brain tissue was
immersed in concentrated nitric acid (300 microliters) overnight, then incubated in a
water bath at 80 degrees Celsius for 20 minutes. The resulting solution was allowed to
cool to room temperature and hydrogen peroxide (300 microliters, 10M solution) was
added to dissolve lipid components. After thirty minutes incubation at room temperature,
the sample was heated to 70 degrees Celsius in the water bath for 15 minutes. The
resultant solution was allowed to cool for 10 minutes, then vortexed thoroughly and
stored until analysis.
Atomic absorption spectrums were measured with a Varian SpectrAA 220Z
atomic absorption spectrometer and processed with SpectrAA software v.4.1. Standard
iron and copper curves were produced from 25, 50, 75 and 100 parts per billion solutions
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of standard iron or copper in nitric acid (Arcos Organics, New Jersey). Standard curve
for zinc was produced from 250, 500, 750 and 1000 parts per billion solutions of standard
zinc in nitric acid (Solutions Plus Inc, Missouri). The spectrometer was zeroed to a
maximum of 0.005 mean absorbance. For total iron measurements samples were diluted
1:40, for zinc measurements samples were diluted 1:10 and for copper samples were
diluted 1:20. Standard furnace settings recommended by Varian were used for the
analysis. All sample values were the mean of six measurements. Concentrations are
calculated to reflect the concentration of the metal in micrograms per gram of native
tissue (wet weight). Significance was determined by the two-tailed, paired Student’s T
test, with α = 0.05.

Results
Two samples were analyzed from each of four brains which were severely
affected by Alzheimer’s disease (Braak and Braak stage VI) (Braak and Braak 1997).
One frozen and one formalin-fixed temporal lobe specimen were obtained from each case
for comparison; the mean duration of archival was four years (range 3-6). Each specimen
was divided into grey and white matter which were analyzed separately. Six
measurements were collected for each sample and the mean of the values was reported in
Figure 1. The mean percent relative standard deviations (%RSD) over these repeated
measures were 0.8% for iron, 12.5% for zinc and 1.8% for copper. The %RSD for zinc
was wider because the concentration in fixed specimens approached the threshold of
detection for this element (%RSD fixed = 20.8, %RSD frozen = 4.1%).
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Figure 1: Effect of long-term formalin archival on transition metal levels in paired
Alzheimer’s disease brain samples
Iron levels were found to decrease by about 43% upon fixation in formalin (p=0.008),
zinc levels were shown to decrease with fixation by about 75% (p<0.0001) and copper
increased by 37% (p=0.03). All of these effects appeared to be independent of whether
the tissue is collected from grey matter or white matter. Lines between specimens
indicate they were taken from the same brain.
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Iron levels in the fixed tissue were significantly lower than in the frozen
specimens (p=0.008 by paired T-test). Seven of the eight specimens examined were
found to have decreased iron after fixation, while one remained essentially unchanged.
On average, iron concentration was 43% lower in the fixed tissue (mean difference 26.2
µg/g tissue, 95% CI 9.1-43.3 µg/g tissue) and both grey and white matter were affected
equally. Brain zinc levels were also found to be notably decreased after fixation
(p<0.0001). This change also affected both grey and white matter and resulted in a mean
decrease in zinc of 19.8 µg/g tissue (95% CI 13.9-25.8 µg/g tissue). Brain copper was
found to be increased in the fixed specimens (p=0.03). This finding was unexpected –
seven out of eight specimens contained higher levels of copper than their frozen
counterparts and the mean increase in copper was 1.65 µg/g tissue (95% CI 0.21-3.09
µg/g).

Discussion
Previous studies have shown that formalin fixation affects the levels of transition
metals in various organs, although it has frequently been argued that most transition
metals in the brain are not affected by fixation. This was primarily determined either by
analysis after a brief fixation period or by indirect means such as determining the
concentration of trace elements in the formalin in which the organ was stored for
comparison to clean formalin (Andrasi 1990, Bush 1995, Gallein 2008). This approach
evaluates transition metal leaching and is obviously sensitive to dilutional variation,
evaporation and contamination from other sources. Additionally, because transition
metal concentrations in most tissues vary considerably between individuals, a non-paired
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analysis may mask the effect of formalin. The most sensitive approach is to obtain paired
samples from each case, one of which is stored by freezing, the other by formalin
archival for several years.
The findings of this study demonstrate that formalin archival of brain samples
affects the concentration of several transition metals. Both iron and zinc were found be
significantly depleted after archival in formalin. Copper, however, was found to increase
with formalin fixation. This increase in copper may be due to contamination of formalin
with copper. While copper levels in formalin are reported to be approximately 2% the
level found in brain (0.1 ppm vs 5 ppm) (Andrasi 1990, Gellein 2007), the Alzheimer’s
disease brain is depleted of copper and over-expresses copper binding proteins such as
ceruloplasmin which may increase the tissue’s copper binding capacity and could in
theory explain the accumulation of copper in the tissue with fixation (Loeffler 1996).
Reports from the literature also indicate that copper levels dramatically increase in AD
brain with fixation, although this was not noted in control tissue which would support this
hypothesis (see Table 1).
The effect of fixation on brain iron has not been previously well-documented,
although we noted that studies which analyzed fixed brain reported different levels of
metals than those analyzing never-fixed brain. Iron levels detected using a micro-PIXE
(particle induced x-ray emission) analysis of formalin fixed Alzheimer’s disease
amygdala were 38.8 µg / g wet tissue while other studies from the same laboratory using
quantitative analyses of never-fixed, Alzheimer’s disease amygdala found a mean iron
concentration of 65.5 µg / g wet tissue (Lovell 1998, Samudralwar 1995, Deibel 1996,
Cornett 1998, Thompson 1988). These studies showed that fixed tissue from the same
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Table 1: Effect of short-term fixation on transition metal concentrations in the
amygdala reported in the literature
Study and
method

38.8 +/- 9.4

[Zinc]
control
22.6 +/- 2.8

N=9

N=5

49.2 +/- 3.3

65.5 +/- 3.8

N = 56

N = 101

Thompson 1988 INAA
Samudralwar 1995 INAA
Deibel 1996 - INAA
Cornett 1998 - INAA
Rulon 2000 - AA

48.9 +/- 3.0

Percent change

Fixed tissue
Lovell 1998 - microPIXE, 24hr formalin
exposure

Never-fixed
tissue

(Two-tailed T test)

[Iron]
control
18.9 +/- 5.3
N=5

[Iron] AD

[Zinc] AD
51.4 +/- 11.0

[Copper]
control
4.4 +/- 1.5

[Copper]
AD
19.3 +/- 6.3

N=9

N=5

N=9

14.5 +/- 0.5

18.2 +/- 0.7

4.1 +/- 0.3

2.7 +/- 0.3

N = 69

N = 119

N = 11

N = 10

60.6 +/- 4.9

14.1 +/- 0.5

17.0 +/- 0.8

-

-

50.8 +/- 3.7

70.8 +/- 4.0

16.7 +/- 0.5

21.4 +/- 0.5

-

-

48.6 +/- 2.2
49.0 +/- 4.0
-

70.8 +/- 6.4
64.0 +/- 3.0
-

15.2 +/- 0.6
13.6 +/- 0.5
15.7 +/- 0.5

19.8 +/- 1.0
17.6 +/- 0.6
16.6 +/- 1.0

4.1 +/- 0.3
-

2.7 +/- 0.3
-

-61 %

-41 %

+56 %

+182 %

+7.3 %

+615 %

p<0.0001
p<0.0001
p<0.0001
p<0.0001
p=0.52
p<0.0001
All six studies listed were published from the same laboratory at the University of Kentucky. One study analyzed fixed tissue; the
others analyzed never-fixed tissue – all used quantitative analytical methods. The never-fixed results are pooled in the second row and
listed individually below. Measurements represent microgram metal per gram tissue, wet weight (results from Deibel 1996 were
converted from dry weight measurements to wet weight). Errors listed are standard deviation. AD = Alzheimer’s disease, PIXE =
particle induced x-ray emission, INAA = instrumental neutron activation analysis, AA = atomic absorption. “Percent change”
indicates the difference between measurements of “Never-fixed” and “Fixed” tissue samples.
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brain region contained 41% less iron than comparable never-fixed tissue, which is
strikingly consistent with the 43% reduction we found in the paired samples in this study.
Additionally, iron concentration in control tissue was found to decrease by even more
(never-fixed 49.2 micrograms/gram versus fixed 18.9 micrograms/g – a 61% reduction,
p<0.0001). The effects on copper levels in these studies were more severe in AD brain
than what we report here. While fixed and frozen amygdala tissue from control brain was
not significantly affected (4.1 vs 4.4 micrograms/gram, p=0.52), AD tissue was reported
to contain 2.7 micrograms copper/gram in never-fixed tissue and 19.3 micrograms/gram
in fixed tissue – a 615% increase (Lovell 1998, Deibel 1996). Finally, zinc levels were
also found to be altered between the studies, although they did not match the results of
our study. Fixation increased zinc levels by 54% in control tissue and by 179% in AD
tissue (Lovell 1998, Thompson 1988, Samudralwar 1995, Deibel 1996, Cornett 1998,
Rulon 2000). Our results found that zinc was depleted by 75% in temporal lobe tissue
from AD patients. The discrepancy in these results may indicate that effects of fixation
differ between brain regions, or with the length of fixation. Additionally, we noted a
wide variance in the effect of fixation on tissue concentrations of all three metals, which
makes it difficult to simply calculate a correction for fixation. Regardless, formalin
fixation (even briefly) appears to destabilize the concentration of multiple metal species
and may affect normal and diseased brain differently. It is therefore necessary to
cautiously interpret transition metal data derived from fixed tissue and future studies
should be limited to fresh or frozen specimens.
Altered homeostasis of iron, zinc and/or copper has been suggested to be involved
in many neurodegenerative diseases; however, reports of metals concentration in these
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tissues have been remarkably disparate in their conclusions. Before seriously considering
the use of chelators or other compounds to manipulate the homeostasis of these essential
biometals, it will be necessary to determine whether and to what degree they are truly
dysregulated. This requires a critical evaluation of the available data. Because a
significant portion of that data was generated from fixed tissue, it may be necessary to reexamine the fundamental assumptions about the role of metals in various
neurodegenerative diseases.
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Abstract
Dysfunctional homeostasis of transition metals is believed to play a role in the
pathogenesis of Alzheimer’s disease (AD). Brain copper, zinc, and particularly iron
overload are widely accepted features of AD which have led to the hypothesis that
oxidative stress generated from aberrant homeostasis of these transition metals might be a
pathogenic mechanism behind AD. This meta-analysis compiled and critically assessed
available quantitative data on brain iron, zinc and copper levels in AD patients compared
to aged controls. The results were heterogeneous as a result of a series of heavily cited
articles from one laboratory that reported large increases in iron in AD neocortex. Seven
laboratories failed to reproduce these findings (p=0.76) – the pooled effect size reported
by these studies was -0.05. Zinc was not increased in the neocortex. Copper was
significantly depleted in AD (p=0.0003). In light of these findings, it will be important to
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re-evaluate the hypothesis that transition metal overload accounts for oxidative injury
noted in AD.

Introduction
The distribution and homeostasis of transition metals in Alzheimer’s disease (AD)
brain and their potential role in the etiology of neurodegeneration has been debated for
six decades or more. Goodman presented one of the earliest arguments for a role of iron
in AD in 1953 with a detailed pathological/histological description of a series of postmortem AD cases. He reported increased Prussian/Turnbull’s blue reactivity indicating
abnormally high levels of tissue iron in a few of these patients. From these findings, he
hypothesized that a defect in iron management may underlie late-onset cognitive loss in
these cases. Hallgren and Sourander in 1958 and 1960 published the first quantitative
analyses of brain iron in Alzheimer’s disease patients using colorimetric techniques. This
failed to demonstrate a significant increase in tissue levels of non-heme iron in AD brain.
However, like Goodman, they noted that many of the specimens showed increased
reactivity to histological iron stains. In the intervening decades, brain iron overload
gradually became widely accepted as a feature of AD (Gerlach 1994, Benzi 1995, Smith
1997, Schipper 1999, Cuajungco 2000). Additionally, the observation that iron, zinc and
copper were concentrated in beta-amyloid plaques led to the hypothesis that oxidative
stress generated from aberrant homeostasis of these transition metals and pathologic
metal-protein interactions might be mechanisms behind the aggregation and toxicity of
senile plaques, ultimately leading to (or contributing to) the neurodegeneration associated
with AD (Lovell 1998, Smith 1997, Markesbery 1999). In vitro studies demonstrated
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that iron, zinc and copper at near-physiologic conditions each bind beta-amyloid and are
capable of precipitating it into aggregates (Bush 1994). The discovery that chelating
these metals from plaques reduced plaque toxicity and increased amyloid solubility in
vitro further supported the metals hypothesis and became a basis for the therapeutic use
of chelators in neurodegenerative conditions (Schubert 1995, Cherny 1999, Rottkamp
2001). Interest in manipulating brain levels of transition metals has risen, resulting in the
development of many pharmacologic chelators and a number of clinical trials (Crapper
McLachlan 1991, Lannfelt 2008, Liu 2010, Squitti 2002).
In the year 2000, one of the most-cited review articles on the subject of metals in
AD declared that “a consensus has emerged in the literature that copper, zinc and iron are
elevated in the AD-affected neocortex” (Bush 2000). The purpose of this study is to
evaluate if that consensus is accurate. The issue remains that most available data on brain
transition metal concentrations is qualitative, and quantitative studies have generally
lacked adequate power to determine whether changes are significant. Additionally,
several of the most prominently cited papers in the field have studied tissue that has been
fixed, which has been shown to compromise the integrity of the data (Lovell 1998,
Jellinger 1990, Schrag 2010). This has made it increasingly important to compile and
critically assess available quantitative data on brain iron, zinc and copper levels in AD
patients compared to aged controls.
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Methods
Literature Search
Literature search was conducted by the first author. Appropriate articles were
assembled by systematic queries of NCBI (PubMed), ISI Web of Science, OVID and
GoogleScholar databases on the 8th of January 2010. Additionally, we reviewed the
citation lists from each article retrieved for the meta-analysis and from relevant review
articles. The indexes of certain journals were manually reviewed, including Journal of
Radioanalytical and Nuclear Chemistry, Trace Elements in Medicine, Trace Elements
and Electrolytes, and Microelement. Articles published in any year up to the date of
search and in any language were included, as long as they were indexed in the databases
described. Quantitative analytical techniques were included in the analysis; semiquantitative approaches were excluded. Acceptable quantitative techniques included
atomic absorption spectroscopy, inductively coupled plasma mass spectrometry or atomic
emission spectroscopy, particle-induced x-ray emission, neutron activation analysis and
colorimetric assays normalized to tissue weight. These methods have been shown to
consistently produce equivalent results (Jervis 1985, Zhang 1997, Stedman 1997).
Search terms therefore included a technique keyword (such as “neutron activation”) and
“Alzheimer’s disease.” General search of high-yield keyword combinations, such as
“iron,” “Alzheimer’s” and “human brain” were also conducted. Abstracts were reviewed
to collect only reports which compared human Alzheimer’s disease brain to aged control
brain for total iron, zinc and/or copper levels in any brain region. Finally, when possible
we contacted an author from each study to request access to any unpublished data and to
clarify methodological details. We were made aware of two unpublished datasets; these
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could not be recovered for inclusion in this meta-analysis, but were described as finding
no significant differences between groups.

Exclusion Criteria
Exclusion criteria were non-quantitative analysis (including normalizing element
concentration to protein concentration), tissue fixation (for any duration of time), the
absence of neuropathological diagnosis and inappropriate control tissue (all cases were
required to be over age 55). Iron has been shown to increase in the brain with age in
neurologically normal subjects; however, it reaches a relatively steady state by about age
55, which is why this was chosen as a cut-off (Hallgren and Sourander 1958, Markesbery
1984). Neuropathologic diagnosis was considered necessary because the clinical
diagnosis of AD is only about 61-84% specific for AD (Gay 2008, Brunnstrom 2009).
Tissue fixation has been shown to alter, sometimes dramatically, the concentrations of
brain metals, either through leaching (iron is reduced on average by 40% in formalin
fixed brain, zinc by as much as 75%), or by concentrating elements through tissue
dehydration or by deposition of metal contaminants which may be present in formalin
(particularly for copper) (Schrag 2010). Finally, normalization of metal levels to protein
concentration was considered unreliable because one study found that much lower
concentrations of protein were isolated from AD tissue compared to normal brain
(Loeffler 1995).
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Data Analysis
The studies which were included reported metals concentrations as either
micromolar concentration or micrograms of metal per milligram of tissue. Tissue
samples were either dessicated or native (referred to as dry weight or wet weight) -- wet
weight was chosen as the standard measure for this study because it is the physiologically
relevant mass. Because dry weight to wet weight conversion ratios have been extensively
published for essentially all brain regions in both Alzheimer’s disease and control brain,
all dry weight measures were converted to wet weight measures. This conversion
affected only two studies and the conversion ratios are included in supp. Table 4 (Andrasi
2000, Deibel 1998). Data from individual studies were collected as means, standard
deviations, and numbers of brains in each group. Effect size was calculated by Hedge’s g
(with a small N bias correction) in a random effects model. Results were presented by
brain region as weighted mean concentrations, and effect sizes. Studies were weighted in
the analysis by inverse variance. Heterogeneity was assessed by Q-test with alpha =
0.05. The metal levels reported for the neocortex were nearly equivalent region-toregion, which enabled analysis of these regions jointly as well as individually. The
pooled neocortical dataset included frontal lobe, temporal lobe, parietal lobe and
hippocampal measurements. Normalcy of distribution was assessed with Lilliefors test
for the pooled neocortical data (Lilleifors 1967). Figures were constructed using an
Excel-based software add-on, MIX 1.7 (Bax 2007).
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Results
Thirty-two studies were identified in the primary screen; twenty studies remained
after the application of objective exclusion criteria. All studies evaluated for inclusion in
the meta-analysis were reported in the annotated references with explanations of the
rationale for inclusion or exclusion. In general, clinical data and demographic
information were limited to age, sex and neuropathological diagnosis at death; comorbid
diseases were generally not described. For this reason, evaluation of potential
confounders was limited. Additionally, only one of the studies reported the use of
blinding in any part of the study (Ward and Mason 1987). The neuropathologic
diagnoses in all cases were limited to parenchymal Alzheimer’s disease pathology -vascular amyloid deposition and Lewy body pathologies were not described.
The main statistical measure we chose to describe the effect of AD on brain iron
was Hedge’s G, hereafter called simply “effect size.” This statistical tool describes the
difference between two groups (here the metal concentration in control brain vs. AD
brain) as a proportion of the pooled standard deviation of the two groups. An effect size
of 1 indicates the experimental group is one standard deviation higher than the control
group. Because of the methodological differences and heterogeneity between the studies,
a random effects model was chosen for the analysis. For datasets which were not
significantly heterogenous, the random effects model yielded equivalent results to the
fixed effects model and analysis in a fixed effects model would not alter the conclusions
of the study.
When neocortical brain regions were analyzed together, the effect of Alzheimer’s
disease on brain iron approached significance (Fig 1; effect size = 0.23, 95%CI -0.07-
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0.53, p=0.13). However, this analysis was complicated by significant heterogeneity.
Heterogeneity in the iron dataset appeared to derive primarily from data published by the
University of Kentucky (U of K) (Fig 2). When hippocampus, frontal, temporal and
parietal lobes were merged to produce a cumulative dataset for analysis of neocortical
iron, the heterogeneity between the U of K studies (4 studies) and all others (11 studies
from 7 independent laboratories) became most evident, Q=26.0 (p=0.017) – the
combined effect size reported by U of K studies alone was 0.67 (95%CI 0.35-1.00,
p<0.0001) while the combined effect size reported by all other studies was -0.05 (95%CI
-0.34-0.25, p=0.76); the latter we feel is the most-accurate estimate of the true effect of
AD on neocortical iron (Fig. 2). With the exclusion of U of K studies, heterogeneity was
reduced to non-significant levels as assessed by the Q test and no evidence of non-normal
distribution was present by the Lilliefors test.
Region by region analysis (after the exclusion of the outlier data source) revealed
significantly increased brain iron in Alzheimer’s disease only in the putamen (supp.
Table 1). Putamen iron levels were increased by 21.4% (effect size 1.14, 95% CI 0.501.78). While only one study apart from those from the U of K measured iron levels in the
amygdala (and it had a very small number of samples), the increase in iron concentration
reported by the U of K was higher than that reported by the independent study.
Additional studies will be needed to determine the true effect size in the amygdala. The
effect size for each neocortical region was non-significant (effect size hippocampus 0.32, 95%CI -0.76-0.11; frontal lobe -0.02, 95%CI -0.41-0.37; temporal lobe 0.56 95%CI
-0.22-1.34; parietal lobe 0.35 95%CI -0.26-0.96).
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There was insufficient data to adequately analyze the effect size of Alzheimer’s
disease on zinc for deep grey matter regions, although results seemed to parallel the
changes in iron (strongest increases were reported for the putamen, globus pallidus and
caudate nucleus). For neocortical regions, heterogeneity was found in the reports of zinc
concentration although the heterogeneity was independent of the laboratory of origin (Fig
1). There was significant change in zinc concentration in the neocortex only in the
parietal lobe (effect size hippocampus -0.08, 95%CI -1.00-0.85; frontal lobe 0.35, 95%CI
-0.24-0.94; temporal lobe 0.47, 95%CI -0.13-1.07; parietal lobe 0.50, 95%CI 0.06-0.94).
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Figure 2: Meta-data of studies reporting the effect of Alzheimer’s disease on
neocortical iron, zinc and copper concentrations
Data from hippocampus, frontal, temporal and parietal lobes were combined to assess
neocortical metal levels. Studies from the University of Kentucky (U of K) are indicated
by red parentheses for iron data. The mean effect size indicated by red vertical lines
includes data reported by U of K. The black vertical line indicates the meta-effect size
for iron when this data source is excluded. There is no significant increase in neocortical
iron in Alzheimer’s brain: effect size = -0.05, 95%CI -0.34-0.25; n= 206 control, 251
AD. There is a trend toward an increase in neocortical zinc, although the dataset is
significantly heterogenous: effect size = 0.26, 95% CI -0.22-0.75; n= 166 control, 118
AD. Copper levels are significantly depleted in Alzheimer’s disease: effect size = -0.59,
95% CI -0.87- -0.31; n= 123 controls, 115 AD.

40

41

Figure 3: Laboratory of origin and not analytical technique appears to be the source
of heterogeneity in measurements of neocortical iron in Alzheimer’s disease.
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Several individual studies indicated an increase in zinc concentration in each
neocortical lobe (supp Table 2).
Copper levels were depleted in the AD group in most regions (supp. Table 3) and
cumulatively neocortical copper was significantly reduced in AD (Fig.1; effect size -0.55,
95%CI -0.85- -0.25, p=0.0003). An additional study (conducted by the U of K) which
was heavily cited and was excluded for tissue fixation, reported a dramatic increase in
copper concentration (>400%) in AD amygdala compared to controls (Lovell 1998).
However, a second report from the same laboratory reported copper was depleted in the
amygdala with an effect size of -1.42, 95%CI -2.40- -0.44. The effect of Alzheimer’s
disease on hippocampal copper was -0.54, 95%CI -0.91- -0.16 and reported effect sizes
for other neocortical regions ranged from -0.39 to -2.78.

Discussion
The data from this meta-analysis indicate that there is a wide-spread
misconception in the scientific literature regarding the levels of several transition metals
in AD brain. For iron levels, this misconception arose from the contributions of one
laboratory which were remarkably dissimilar to other published reports and were heavily
cited. Despite the fact that the U of K studies reported findings which were not
reproduced by seven other laboratories, it was necessary to consider whether these
discrepant reports could reflect the true effect size. However, we found no obvious
quality measures between the studies which would account for the discrepancy. While
brain iron concentration increases with aging and differences could therefore be
attributed differences in age between control and AD groups, this was well-controlled in
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study selection and control patients were over 55 years of age (Hallgren and Sourander
1958). The possibility that different analytical techniques could contribute to
heterogeneous findings was also considered; however, the techniques employed in these
studies have been shown to produce compatible results and five additional studies which
did not originate at U of K also utilized INAA-based measurements (the technique
employed in the U of K studies) without detecting significant changes (Andrasi 2000,
Panayi 2001, 2002, Rulon 2000, Thompson 1988). This suggests the artifact was not
dependent on the analytical technique employed (Fig 2). Moreover, no differences in the
methodology of tissue preparation between these studies would be expected to produce
the discrepant results observed here. While we were not been able to precisely identify
the source of the artifact in this dataset, we felt confident in drawing conclusions from the
non-U of K studies. We therefore concluded that Alzheimer’s disease did not alter
neocortical iron levels and there was no evidence for a global dysregulation in brain iron
in Alzheimer’s disease as has frequently been suggested. Iron was modestly elevated in
the AD putamen over controls, but no other brain region appeared to be affected. The
increases in tissue iron in the deep grey matter may be a significant component of
Alzheimer’s disease pathology, but they certainly do not account for the neocortical
dysfunction observed in this disease. Moreover, AD is commonly comorbid with some
degree of Lewy body disease which is strongly associated with increases in basal ganglia
iron -- the findings in the putamen may be more reflective of this disease process
(Hamilton 2000, Dexter 1991). Gradient echo T2* (GRE-T2*) and susceptibility
weighted imaging (SWI) are iron-sensitive sequences that have been used to follow brain
iron levels in AD patients (Chavan 2009, Kirsch 2009). Several large studies of this
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technology have been conducted to evaluate the usefulness of following brain iron levels
as a biomarker of AD. In these studies the putamen was the only region consistently
found to contain increased levels of iron in AD (Kirsch 2009, Zhu 2009, Ding 2009).
This is remarkably consistent with the results of this meta-analysis and validates the
utility of this technology for noninvasively estimating tissue iron levels. However,
increases in putamen iron are not specific to AD and therefore may not be particularly
helpful in establishing a diagnosis.
Zinc levels reported in the neocortex were heterogeneous even after the exclusion
of the University of Kentucky data. No significant increases were found for any region,
although individual studies reported increases in the frontal and temporal cortex and the
hippocampus. The heterogeneity of these results may be due to differences in tissue
sampling.
Among the most important observations of this study is the prominent depletion
of copper in AD. Insufficient data is currently available to enable a detailed regional
assessment of alterations in copper levels in AD, but the available evidence suggests that
copper is generally depleted in AD (although copper is noted to increase in the putamen
by one study). There are widely discrepant results from U of K studies on the amygdala,
one indicating decreased copper in AD (effect size -4.32, 95%CI -6.00- -2.63), one
(excluded for tissue fixation) indicating more than four fold increased copper levels. The
latter study is the most cited study on the subject of copper in AD and is the source for
numerous articles reporting that copper levels are (several fold) increased in AD – several
of which argue strongly in favor of clinical trials of metal chelation (Religa 2006,
Cuajungco 2000, Rottkamp 2001, Bush 2000, Filiz 2008). It is important to clarify that
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copper is not increased in AD brain. A clinical trial of D-penicillamine, a copper
chelator, was unable to produce any clinical improvement in the treated cohort (in fact
patients trended toward worse outcomes) and patients experienced numerous toxicities
resulting in one death and the early suspension of the trial (Squitti 2002).
Focal alterations in metals distribution have been suggested by several studies to
be associated with the primary pathologies of AD. All three metals evaluated here are
reported to accumulate within senile plaques, although other studies call into question the
consistency of this observation. One study found 30% of plaques had no detectable iron
in them while a few of the largest plaques had high concentrations of magnetite. Because
of the inhomogeneous distribution of metals in the brain, there is little doubt that
sampling method is an important variable.
Based upon these cumulative findings and because of the disproportionate impact
of outlier data on the literature, we feel it will be important to re-evaluate brain metalsoverload hypotheses particularly when considering additional clinical trials of metal
chelating/modulating therapies. It is fundamentally important that the application of
metal-targeted pharmacology restores not only normal metal levels, but also normal
transition metal physiology. For these reasons, we argue that further cautious study is
necessary before exposing a large, vulnerable clinical population to potentially toxic
chelating agents.
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Abstract
Cerebral amyloid angiopathy (CAA) is a vascular lesion associated with
Alzheimer’s disease (AD), is present in as many as 95% of AD patients and produces
MRI-detectable microbleeds in many of these patients. It is possible that CAA-related
microbleeding is a source of pathological iron in the AD brain. Because the homeostasis
of copper, iron and zinc are so intimately linked, we determined whether CAA
contributes to changes in the brain levels of these metals. We obtained brain tissue at
autopsy from the temporal lobes of AD patients with severe CAA to compare to AD
patients without evidence of vascular amyloid. Patients with severe CAA had
significantly higher non-heme iron levels. Histological analysis demonstrated that iron
was deposited in the walls of large CAA-affected vessels. Zinc levels were significantly
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elevated in grey matter in both the CAA and non-CAA AD tissue, but no vascular
staining was noted in CAA cases. Copper levels were decreased in both CAA and nonCAA AD tissues and copper was found to be prominently deposited on the vasculature in
CAA. Together, these findings demonstrate that CAA is a significant variable affecting
transition metals in AD.

Introduction
There is considerable interest in understanding transition metal homeostasis in the
brain, particularly in Alzheimer’s disease (AD) research. The AD neocortex is frequently
stated to contain increased iron levels at the tissue level. Numerous review articles have
suggested that AD brain contains two to five fold more iron than control tissue
(Avramovich-Tirosh 2008, Bush and Tanzi 2008, Molina-Holgado 2007, Huang 2004).
Remarkably, most quantitative measurements of brain iron failed to show any increase in
neocortical iron in AD (Andrasi 2000, Corrigan 1991, Griffiths and Crossman 1993,
Hallgren and Sourander 1960, Magaki 2007, Panayi 2001, Plantin 1987, Religa 2006,
Stedman and Spyrou 1997, Ward and Mason 1987).
Never-the-less, increases in iron levels in the deep grey matter structures of the
brain in patients with AD have been clearly demonstrated and other disturbances in iron
levels and distribution may be more easily detected in qualitative studies (Andrasi 2000,
Corrigan 1991, Griffiths and Crossman 1993). However, despite extensive investigation,
the source of this abnormal iron remains a matter of debate; it may represent a metabolic
derangement, abnormal deposition or clearance or perhaps some other explanation.
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Cerebral amyloid angiopathy (CAA) is a vascular manifestation of AD which is
present in as many as 95% of AD patients and can produce MRI-detectable microbleeds
even in patients with only mild cognitive impairment (Jellinger 2010, Kirsch 2007,
Schrag 2010). Vascular amyloid deposition results in loss of vascular smooth muscle
cells (particularly in arterioles), and thickening of the vessel wall with congophilic
material. These changes result in fragility of the microvascular system, although the
exact mechanism which undermines its stability is not known (Vinters 1987, Vinters
1996). Several studies have demonstrated that iron-rich deposits staining positive for
beta-amyloid are preferentially distributed near vascular elements, which may suggest
that microbleeding could be a catalyst for the formation of AD-like pathologic lesions
(Goodman 1953, Cullen 2005, 2006). Because of the near-ubiquitous presence of CAA
in the context of AD, it is possible that CAA-related microbleeding is a source (perhaps
the major source) of pathological iron in AD brain. In this study we assessed this
hypothesis by determining the levels of various metals by both analytical and qualitative
techniques in groups of cases with severe AD and either severe or negligible CAA.

Materials and Methods
Tissue Selection
Post mortem tissue was obtained from the Alzheimer’s Disease Research Center
Brain Bank at the University of California, Los Angeles. All patients and/or their
surrogates had consented to participate in research protocols prior to tissue donation. The
research was approved by the Institutional Review Board of Loma Linda University
Medical Center (approval #54174). Both frozen tissue specimens and fixed tissues were
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available for study. Neuropathologic examination at the time of autopsy included Braak
and Braak staging of AD and Vonsattel grading of CAA pathology (Vinters and
Vonsattel 2000, Braak and Braak 1991, Greenberg 1997). Vonsattel staging describes
the severity of CAA as follows: stage 1- β-amyloid deposition limited to the basement
membrane of arterioles and primarily involving leptomeningeal vessels; stage 2- βamyloid deposited between vascular smooth muscle cells and pathology extends to
penetrating arterioles and stage 3- β-amyloid largely replaces vascular smooth muscle in
arterioles. Microaneurysms and microhemorrhages often occur with Vonsattel stage 3
CAA.
Frozen tissue was isolated from the superior or middle temporal lobe gyrus for
three groups of patients; six samples were obtained for an aged neurological control
group, along with eight AD samples without evidence of significant CAA (Vonsattel
grades 0-1) and eight AD samples with severe CAA (grade 3). Patient demographics are
listed in Table 6.

Atomic Absorption Spectrometry
Metals measurements were conducted as previously described (Schrag 2010).
Blocks of grey matter and white matter weighing between 30-60mg were cut from the
donated specimens. For total iron, copper and zinc determination, tissue was prepared by
nitric acid ashing. Brain tissue was covered in concentrated nitric acid (300µL)
overnight, then incubated in a water bath at 80°C for 20 minutes. The solution was
allowed to cool to room temperature for 10 minutes. Hydrogen peroxide (300 µL of 10M
solution) was then added to dissolve the lipid components and allowed to incubate at
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room temperature for 30 minutes. The mixture was then incubated at 70°C in the water
bath for 15 minutes. The resulting solution was allowed to cool to room temperature for
ten minutes, thoroughly vortexed, then frozen until needed.
For non-heme iron extraction, 260µL of 500µM EDTA was added to brain
regions which were then homogenized. One hundred microliters of trichloroacetic acid
(20% solution in 500µM EDTA) was added and thoroughly vortexed before incubating at
90°C for 30 minutes. Finally, 700µL of the EDTA solution was added and thoroughly
vortexed. The resulting suspension was centrifuged at 13,000 g for 10 minutes and the
supernatant was collected as the non-heme iron sample.
Atomic absorption spectra were measured with a Varian SpectrAA 220Z atomic
absorption spectrometer and processed with SpectrAA software v.4.1 (Varian Inc.,
California). Standard iron and copper curves were produced from 25, 50, 75 and 100
parts per billion solutions of standard iron or copper in nitric acid (Arcos Organics, New
Jersey). Standard curve for zinc was produced from 250, 500, 750 and 1000 parts per
billion solutions of standard zinc in nitric acid (Solutions Plus Inc, Missouri). The
spectrometer was zeroed to a maximum of 0.005 mean absorbance. For total iron
measurements samples were diluted 1:40, for non-heme iron samples were diluted 1:20,
for zinc measurements samples were diluted 1:10 and for copper samples were diluted
1:20. All sample values presented in Table 7 are the mean of six measurements.

Histology
Frozen sections were prepared for four of the patients from each group for
histology. Histological slides were prepared on a Leica cryostat with either 14 or 20
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micrometer thick sections of brain tissue containing both an intact portion of the cortical
ribbon and adjacent white matter. Iron staining was accomplished with modified
Prussian Blue and Turnbull’s blue methods on the 20 micrometer thick sections.
Prolonged incubation times were employed to increase the sensitivity of the techniques
(Smith 1997 and Cullen 2005, 2006). Ideal incubation times for aged brain to balance
signal to background-noise ratio were optimized to 48 hours. Frozen sections were
allowed to dry at room temperature for ten minutes and then briefly fixed for 10 minutes
in absolute methanol. While staining of never-fixed tissue is preferred to limit the
possibility of leaching metals from the tissue, unfixed brain tissue was not stable
throughout the long staining procedure. Methanol-fixation has been shown in a study
using hepatocytes to preserve iron levels far better than formalin-containing fixatives
(Okon 1998). Staining solutions for each probe were prepared as 5% potassium
ferrocyanide (for Prussian Blue labeling of ferric iron) or 5% potassium ferricyanide (for
Turnbull’s blue labeling of ferrous iron) dissolved in an aqueous solution with 10%
hydrochloric acid. After 24 hours’ exposure, the staining solution was replaced with
fresh solution for a further 24 hours. The sections were then washed in distilled
deionized water, dehydrated through 100% ethanol, cleared in xylene and mounted in a
resinous medium (Permount, Fisher Scientific). The slides were imaged on a Leica
DM50 light microscope (Leica Microsystems, Illinois), at least five fields containing
arterioles and five of capillaries were captured from each slide.
Zinc was visualized using a fluorescein-conjugated probe, ZP4, as follows.
Frozen, 14 micron sections were allowed to dry at room temperature for 10 minutes and
were then placed in PBS for 30 minutes. A 2 micromolar solution of the zinc probe in

66

PBS was prepared and gently pipetted over the section. After a ten minute incubation,
the sections were washed three times in PBS for 10 minutes each. Care was taken to
minimize agitation to prevent damage to the unfixed tissue section. A thin paraffin
spacer was placed on the slide and the section was coverslipped with aqueous mounting
medium containing DAPI. The slide was then immediately imaged on an Olympus
confocal microscope (Olympus America Inc., Pennsylvania).
Copper was imaged using a turn-on probe with a boron-dipyrromethene
(BODIPY) fluorophore, copper sensor 1 (CS1). The fluorescent yield from this probe
has been reported to increase 10 fold upon binding to monovalent copper (Miller 2006,
Zeng 2006, Domaille 2008). Sections were allowed to dry for ten minutes, permeabilized
in Triton-X in PBS for ten minutes and finally washed gently in PBS for ten additional
minutes. A 2 micromolar solution of the CS1 probe was prepared and pipetted over the
section. After ten minutes, the excess probe was tapped off the slide which was then
mounted with a thin paraffin spacer in aqueous mounting medium containing DAPI
(Vector Labs, California). For colocalization of vascular copper deposits with betaamyloid, we added a ten-minute incubation of the section in 1% Thioflavin-S solution
followed by thorough washing to the procedure prior to the CS1 incubation.

Electrophoresis
Protein levels of heme degradation enzymes were determined by denaturing SDSPAGE and western blot. Briefly, tissue samples were isolated containing roughly equal
proportions of white and grey matter from the temporal lobe. The tissue was
homogenized in an ice cold sucrose buffer containing a protease inhibitor cocktail. The
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tissue was disrupted with seven strokes with a fitted Teflon pestle in a glass
homogenization tube. Crude nuclear debris was cleared from the suspension by
centrifugation at 1000g for 15 minutes. Total protein concentration was determined in
the supernatant by the Bradford assay (Pierce Laboratories, Illinois). Samples were
prepared for electrophoresis by adding 25% v/v loading buffer (Invitrogen, California)
and 10% v/v beta-mercaptoethanol and heating at 95°C for ten minutes. Fifteen
micrograms of total protein were loaded into each lane of a 10% polyacrylamide gel and
electrophoresed at 100V in a MiniProtean Tetra System (BioRad Laboratories,
California). The proteins were then transferred to a nitrocellulose membrane at 30V for
four hours. The resulting blot was blocked in an albumin-based blocking buffer
(Invitrogen) and probed with either mouse monoclonal beta-actin (1:1000), rabbit
monoclonal heme oxygenase 1 (HO-1) (1:100), mouse monoclonal HO-2 (1:500), mouse
monoclonal biliverdin reductase A (BLVD R A) (1:200) or mouse monoclonal BLVD R
B (1:200) antibodies (all from Abcam, Cambridge, Massachusetts). After an overnight
incubation at 4°C, the blots were thoroughly washed with TBS buffer containing 0.05%
Tween-20 and a fluorescently labeled goat anti-mouse or rabbit secondary (IRDye, Licor)
was applied. After a two-hour incubation the blots were washed again and visualized on
an Odyssey Infrared Imaging System (Licor Biosciences, Nebraska). Optical density was
determined using Odyssey 2.0 software and data were collected as the relative intensity
of the band of interest compared to the corresponding loading control band.
Clear native acrylamide electrophoresis was conducted to validate staining from
the CS1 copper probe. Non-denaturing conditions were required to ensure proteins
retained any bound copper (Finney 2010). The homogenate was prepared as previously
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described except EDTA was omitted from the protease inhibitor cocktail to prevent metal
chelation. To 500 microliters of homogenate, 120 microliters of 20% digitonin was
added to solubilize the membrane components. Crude nuclear debris was then removed
by centrifugation at 1000g. Finally, 20 microliters of 50% glycerol and 0.1% Ponceau-S
dye were added to the sample. Fifty micrograms of total protein were loaded into a
gradient 4-13% acrylamide gel (prepared without SDS) and run on ice at 250V overnight.
Running buffer consisted of 50 mM Tris, and 7.5 mM imidazole; 0.05 % deoxycholate
and 0.05% Triton-X-100 were added to the cathode buffer.
The gel was probed with 2mM CS1 solution for ten minutes and copper-positive
bands were detected by red fluorescence. Confirmation that fluorescent bands were in
fact copper-positive was determined by incubating the gel with 1% bathocuproine sulfate
(BCS), a copper chelator, for 48 hours and observing the reduction in fluorescence.
Additionally, fluorescent bands were cut from the gel and analyzed for copper content as
follows. The band of interest was carefully weighed and incubated with 600 microliters
concentrated nitric acid for 2 hours. It was then heated to 80°C in a water bath for ten
minutes. The resulting sample was then analyzed by atomic absorption spectrometry as
previously described.
All measurements are reported as mean +/- standard deviation. Significance was
assessed by the Students T test (two-tailed) with alpha of p=0.05.
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TABLE 6: Patient demographics and neuropathologic findings

70

TABLE 7: Temporal lobe metal concentrations

Data presented as µg metal/g wet tissue +/- standard deviation
*p<0.05, **p<0.01 compared to control
Ψ
p<0.05 compared to Alzheimer’s disease w/o significant cerebral amyloid angiopathy
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Results
Twenty-two brain samples were obtained from the temporal lobes of elderly
humans at autopsy. Cases included in the study were carefully chosen based upon their
neuropathologic findings. A group of cases with AD was assessed for the severity of
vascular β-amyloid deposition. Eight cases demonstrating severe cerebral amyloid
angiopathy were included in one group, eight with minimal to no cerebral amyloid
angiopathy were included in another – all patients in both of these groups demonstrated
severe parenchymal AD pathology. Additionally, six cases with no evident
neuropathologic abnormalities and matching age distribution were included as controls
(Table 6). This study design was chosen to delineate pathologic changes associated with
vascular degeneration from the effects of parenchymal Alzheimer’s pathology. The
tissue was selected from the middle and superior temporal gyri, a region significant to
AD, and was preserved by flash freezing over liquid nitrogen at the time of autopsy; the
sample was never exposed to fixative.
The level of metals in the tissue was determined by atomic absorption
spectrometry (Table 7). Total iron was measured because the majority of other measures
of brain iron in AD reported in the literature have been performed by measuring total
iron. However, because substantial blood remains trapped within the vasculature in this
post-mortem tissue, measurement of non-heme (chelatable) iron was considered a morereliable measure of tissue iron content. Total iron was found to be significantly increased
in the group with CAA, compared to the AD group without CAA, in white matter
measurements (p=0.036). Iron levels in the AD group without CAA were nonsignificantly lower than those in the control group. No significant differences were noted
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in the grey matter measurements between the groups. Non-heme iron measurements
confirmed the significant increase in white matter iron in the CAA group compared to the
AD-only group (p=0.032) and the CAA group trended strongly toward an increase
compared to normal controls as well (p=0.097). There was no difference in non-heme
iron levels in the white matter between the AD-only group and the controls. In the grey
matter, iron was again significantly increased in the group with CAA compared to the
control group (p=0.020) while the AD-only group was not significantly different from the
controls. In the absence of vascular pathology, no alteration in brain iron content could
be detected in AD brain compared to normal aged control brain.
Histologically, Prussian blue and Turnbull’s blue staining were used to determine
the distribution of ferrous and ferric iron in these specimens. Turnbull’s blue
preferentially reacts with divalent iron and brightly stained the walls of arterioles in the
CAA group while this staining was absent from specimens from both of the other groups
(Fig. 4). Prussian blue staining of ferric iron was not prominent and did not stain the
vasculature in any group except in areas of obvious hemorrhage (not shown). Little
staining of amyloid plaques was noted, although demonstration of iron in amyloid
plaques is typically accomplished with DAB-enhancement of iron stains, which was not
done here.
To reinforce the hypothesis that iron deposition in AD is a result of
microbleeding, we observed the levels of heme degradation enzymes (Fig. 5). The
expression of several of these enzymes is inducible in the presence of extravascular heme
and would therefore be expected to be elevated in the context of ongoing microbleeding.
Two isoforms of heme oxygenase are responsible for catalyzing the degradation of heme
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Figure 4: Iron is deposited on arterioles in cerebral amyloid angiopathic brain
Turnbull’s blue stain of control, AD brain without CAA and AD brain with CAA
demonstrates deposition of ferrous iron in the wall of an arteriole affected by CAA.

75

76

Figure 5: Heme degradation enzymes are induced in cerebral amyloid angiopathic
brain but not in purely parenchymal Alzheimer’s disease brain
Representative western blots for the major enzymes involved in heme degradation are
shown at left above. One isoform each of heme oxygenase (HO-1) and biliverdin
reductase (BLVD R B) are substantially elevated in tissue with severe CAA compared to
both normal control tissue and AD tissue without CAA. There is no significant
difference between AD without CAA and controls. These results support the hypothesis
that increased iron in AD is primarily a result of microbleeding.
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into biliverdin, carbon monoxide and free iron. HO-1 is the major inducible form, and
HO-2 is generally constitutively expressed. HO-1 was significantly elevated in the group
with CAA and was at comparable levels in both of the other groups. HO-2 levels were
not significantly different between groups. As heme oxygenase is inducible by a variety
of molecules, alterations in its expression are non-specific for microbleeding so we also
studied the next enzymes in the heme degradation pathway, biliverdin reductases A and
B. We found that while biliverdin reductase A levels were unchanged between groups,
biliverdin reductase B levels were significantly increased in the CAA group over both the
control and AD-only group, indeed more than three fold over the AD-only group. These
findings strongly support the hypothesis that the increases in iron in the CAA group are
the result of ongoing microvascular bleeding.
Zinc levels were also measured by atomic absorption spectrometry. No
significant differences were noted among the groups in zinc measurements from the
white matter. Both CAA and AD-only groups had significantly more zinc in the grey
matter than the control group (p=0.0035 and p=0.019 respectively). Changes in zinc
levels appear restricted to the grey matter. Histological analysis of zinc distribution with
fluorescent probe ZP4 mirrored the findings of the atomic absorption with a moderate
increase in staining of zinc in grey matter from the AD groups. No prominent labeling of
the vasculature was noted in any of the groups (Fig. 6).
Copper measurements by atomic absorption spectrometry demonstrated
significant abnormalities. Both CAA and AD-only group had significantly lower levels
of copper in the white matter than the controls (p=0.023 and p=0.031 respectively).
Changes in the grey matter were even more dramatic with both the CAA and AD-only
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Figure 6: Increased non-synaptic zinc levels in grey matter in Alzheimer’s disease
Non-synaptic zinc was visualized using the green fluorescent ZP4 probe. Zinc is
concentrated in the grey matter of both AD groups compared to normal control. Nonsynaptic zinc is primarily distributed in a perinuclear pattern as shown in the inset of the
image on the right. Zinc deposition on the vasculature was not prominent in any group.
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group again having less copper than the controls (p=0.011 and p=0.0069 respectively).
To qualitatively assess the distribution of copper we used a recently developed copper
probe, copper sensor 1 or CS1 (Miller 2006, Zeng 2006, Domaille 2008). This probe is a
BODIPY-conjugated turn-on probe whose fluorescent yield is reported to increase by ten
fold upon binding to monovalent copper. Notably, the probe is selective for monovalent
copper only; no appreciable signal was reported by divalent copper. Because this probe
had not been previously used in histological applications, we performed a number of
control experiments to ensure that the fluorescent signal generated from this probe
represented true copper binding (Fig. 7). We assessed the ability of the probe to detect
protein-bound copper since virtually all copper in the brain is bound. To accomplish this,
we electrophoresed brain protein homogenates under non-denaturing conditions (and
without Coomassie dye which interferes with the fluorescent signal) and probed the
resulting gel with CS1. Several bands were cut from the gel and analyzed by atomic
absorption spectrometry and those that were fluorescent contained considerably more
copper that those that were not. Forty-eight hour incubation of the gel with 1% BCS, a
copper chelator, obliterated the fluorescent signal. Finally, we ran purified
ceruloplasmin, a protein which selectively binds divalent copper, to veridy selective
monovalent copper detection by the probe. No fluorescent signal was detected
corresponding to the ceruloplasmin band on Coomanssie stain, although a considerable
concentration of copper was detected by AA. When the probe was applied to brain
tissue, BCS copper chelation of the tissue section obliterated any red-fluorescent signal.
CS1 staining of tissue sections revealed discrete peri-nuclear puncta of intense red
fluorescence in all three groups. This pattern of staining is consistent with the pattern of
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Figure 7: Copper is concentrated in vascular elements in CAA
Images A and B show control brain cortex stained with CS1 probe (red) and DAPI.
Image B was stained after the tissue was incubated in BCS, a selective copper chelator.
BCS incubation reduces fluorescence from the CS1 probe, confirming that the bulk of the
red signal is from copper binding. Image C shows a portion of a native protein
electrophoresis of a brain homogenate. A band binding the CS1 probe was located. An
adjacent protein band (determined by Coomassie staining) along with the positive band
were analyzed by atomic absorption spectroscopy. The concentration of copper in the
positive band was more than double that in the negative band. Additionally, purified
ceruloplasmin (Cp in image C) which is known to bind divalent copper did not fluoresce
upon CS1 incubation, confirming the valence selectivity of the probe. Images D, E and F
show CS1 and DAPI staining of control, AD only and AD with CAA brain respectively.
Monovalent copper is prominently deposited on vessels in the CAA case. Images G, H, I
and J, K, L show thioflavin staining of beta-amyloid (G and J) overlaid on CS1 stain for
copper (H and K) in CAA-affected brain. Copper appears to strongly colocalize with
thioflavin staining of beta-amyloid (green) in a CAA vessel, but only weakly in betaamyloid plaque.

83

staining of key copper-binding proteins reported in other studies. Importantly, in the
CAA group remarkable staining of the vasculature was observed in the grey matter. Both
capillaries and arterioles were stained and the copper staining was noted to colocalize
with the fluorescence from the thioflavin-S stain for beta-amyloid.
For historical interest, we also measured aluminum in these tissues – no
significance difference between the groups was detected, but variance in aluminum levels
was high for all groups.

Discussion
The metabolism of iron in the brain and how it changes with aging and AD has
been studied in depth. Total iron levels increase throughout the brain with age under
normal conditions, particularly in the putamen, reaching a relatively steady concentration
by about the sixth decade of life (Hallgren and Sourander 1958, Markesbery 1984).
Elevated levels of tissue metals can cause neuronal injury through a number of
mechanisms. Both iron and copper are redox active metals, capable of generating freeradicals as they cycle between valence states. Oxidative injury in the form of lipid
peroxidation, protein crosslinking and DNA damage have been reported as early
pathologic findings in the process of Alzheimer’s neurodegeneration -- injuries which
result from uncontrolled reactive oxygen species whose formation could be catalyzed by
abnormal free iron (Markesbery 1999 and Smith 2007). Additionally, the β-amyloid
plaques characteristic of AD have been described as a sort of “metals sink” because
copper, zinc and in particular iron are thought to be concentrated at their cores (Goodman
1953, Lovell 1997). While many, perhaps even most, β-amyloid plaques in human brain
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contain no more iron than normal brain tissue (in fact, one study found 30% had no
detectable iron whatever), some plaques (particularly larger ones) have been shown to
contain high concentrations of a reactive iron oxide, magnetite (Dhenain 2002,
Collingwood 2008). Iron-binding appears to increase the toxicity of β-amyloid -- when
amyloid is incubated with a strong metal chelator prior to its application to neurons in
vitro, its toxic effects are dramatically ameliorated (Rottkamp 2001). For this reason,
therapies to manipulate brain iron levels have been tested in human trials (Crapper
McLachlan 1991, Lannfelt 2008).
Pathologic accumulation of iron has been hypothesized to be a result of abnormal
expression patterns of iron regulatory proteins (IRPs), the master regulators of brain iron
(Smith 1998). The expression of IRPs is directly affected by tissue iron levels and alters
the expression of numerous iron binding proteins, including storage molecules like
ferritin, iron transport molecules like transferrin, transferrin-receptor and divalent metal
transporter 1 and certain key proteins related to AD, including amyloid precursor protein.
IRPs bind to iron-response elements in untranslated regions (UTRs) of the affected genes,
upregulating gene expression if they bind in a 5’ UTR, downregulating expression when
binding is in a 3’ UTR (Leipuviene 2007, Rogers 2008, Avramovich-Tirosh 2008). This
elaborate system intricately regulates the homeostasis of brain iron and appears to remain
largely intact in the AD brain. We previously showed that the level and pattern of
expression of IRP1 and IRP2 are unchanged in AD brain compared to normal aged brain
and while reports vary, the majority of evidence suggests ferritin, transferrin and
transferrin-receptor levels are essentially unchanged (Magaki 2007, Connor 1992, Beard
1993, Loeffler 1995). Because the metabolic handling of iron appears to be essentially
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intact in AD, we chose to assess whether abnormal deposition of iron through
microbleeding may account for the qualitative increases reported by various
investigators.
The novel component of the design of this study is the stratification of AD cases
by the degree of vascular amyloid pathology to determine whether the increased iron
often reported in AD is associated with, or the result of, parenchymal or vascular
pathology. CAA pathology in AD exists as a spectrum ranging from nearly undetectable
in some cases to the predominant neuropathologic abnormality in others (Greenberg
1997). For this reason, the stratification employed here is somewhat arbitrary; it is a
useful distinction.
The current study, in the context of previous work, leaves little doubt that iron
deposition in AD may be linked to microvascular bleeding or leakage. Iron levels were
only increased in the CAA group and this increase was found to be associated with
vascular accumulation of ferrous iron. Moreover, the heme degradation enzymes HO-1
and BLVDR B were significantly elevated in the CAA group over both the normal
controls and the non-CAA AD cases. Increases in heme oxygenase 1 in AD have been
previously well-documented, but the finding of increased biliverdin reductase B is a new
observation and quite interesting. This reductase, in addition to its role in heme
degradation, functions as both a dual specificity serine/threonine/tyrosine kinase and a
leucine zipper-type transcription factor which promotes the expression of heme
oxygenase 1 among other targets (Lerner-Marmarosh 2005, Florczyk 2008). These
features hint at a more prominent role for this molecule in the pathologies of AD than has
previously been appreciated. Curiously, in a recently published prospective study peptide

86

fragments from both heme oxygenase 1 and biliverdin reductase B were shown to be
elevated in serum of subjects with mild cognitive impairment who subsequently
progressed to late-onset dementia in comparison to subjects with equally severe mild
cognitive impairment who remained cognitively stable (Mueller 2010). We have now
shown that both enzymes are directly involved in vascular AD pathology – that they are
detectable in peripheral blood samples makes them potentially valuable as biomarkers of
AD. CAA-related microbleeding is additionally often detectable by susceptibility
weighted MRI at early stages of cognitive impairment (Kirsch 2009, Schrag 2010). Iron
modulation has been considered as a potential therapy for AD, although initial clinical
trials have not yet shown an improvement in cognitive performance (Crapper McLachlan
1991, Lannfelt 2008). Because these biomarkers are available, future clinical trials may
be designed to treat a subset of patients with identifiable microbleeding rather than all
patients presenting with cognitive decline.
The significance of zinc levels in the neocortex of brain affected by AD has been
debated for decades. Several studies have shown an increase in zinc in AD neocortex
(Cornett 1998, Corrigan 1993, Deibel 1996, Religa 2006, Ward and Mason 1987) while
others have found no significant increase (Andrasi 2000, Panayi 2002) and one study
found a decrease in zinc (Corrigan 1991). Our result demonstrates that zinc is increased
in AD only in grey matter. Previous studies have examined tissue samples that included
both grey and white matter together, so discrepancies may be due to differences in tissue
sampling. While a previous study convincingly showed that zinc was deposited on the
vasculature in an animal model of CAA, our results suggest that alterations in zinc may
not be strongly associated with vascular β-amyloid in human CAA (Friedlich 2004).
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Copper levels are generally reported to decrease in AD (Diebel 1996, Magaki
2007). One often-cited study reports an increase in copper, although this is likely
artifactual due to tissue fixation, which has been shown to increase apparent tissue copper
levels in AD (Lovell 1998, Schrag 2010). Our results demonstrate a significant decrease
in copper in both white and grey matter across both AD groups studied. Monovalent
copper was also noted to be deposited on vascular elements affected by CAA using a
novel fluorescent probe. Curiously, no staining of copper was noted in β-amyloid
plaques in these studies which may mean that copper associated with plaques is primarily
in the divalent form. The perinuclear punctate staining pattern of monovalent copper was
observed in specimens from all three groups of cases and likely represents an
endoplasmic reticular and trans-golgi distribution (Yang 2005). A similar pattern of
staining has been observed for several key neuronal copper binding proteins including
ATP7A, ATOX1, and Steap2 which are associated with these subcellular structures
(Tokuda 2009, El Meskini 2007, Prohaska 2004). The CS1 probe has enabled this initial
histological analysis of monovalent copper in AD and will no doubt lead to future studies
clarifying the neurobiology and neuropathology of brain copper.
For decades there has been substantial interest in the role of metals in AD and in
manipulating the homeostasis of these metals as therapy -- this interest will likely
continue. However, clinical trials of chelators and chelator-like compounds have
demonstrated substantial toxic effects and one has claimed the life of a patient-participant
(Squitti 2002). For this reason, more detail is needed in the analysis of the role of these
metals and the associated metabolic pathways in disease to identify the best ways to
intervene.

88

Acknowledgements
This research was funded by the National Institutes of Health (AG20948). Harry
V. Vinters is supported in part by P01 AG12435, P50 AG16570 and the Daljit S. and
Elaine Sarkaria Chair in Diagnostic Medicine. Christopher J. Chang is an investigator
with the Howard Hughes Medical Institute and is funded through the NIH (GM79465).
None of the authors report conflicts of interest related to this material.

89

References
1.

Andrasi E, Farkas E, Gawlik D, et al (2000) Brain iron and zinc contents of German
patients with Alzheimer’s disease. Journal of Alzheimer’s Disease 2:17-26.

2.

Avramovich-Tirosh Y, Amit T, Bar-Am O, et al (2008) Physiological and
pathological aspects of Abeta in iron homeostasis via 5’UTR in the APP mRNA and
the therapeutic use of iron-chelators. BMC Neurosci 9 suppl:S2.

3.

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes.
Acta Neuropathol 82:239-59.

4.

Bush A, Tanzi R (2008) Therapeutics for Alzheimer’s disease based on the metal
hypothesis. Neurotherapeutics 5:421-32.

5.

Collingwood J, Chong R, Kasama T, et al (2008) Three-dimensional tomographic
imaging and characterization of iron compounds within Alzheimer’s plaque core
material. J Alz Dis 14:235-45.

6.

Connor J, Snyder B, Beard J, et al (1992) Regional distribution of iron and ironregulatory proteins in the brain in aging and Alzheimer’s disease. Journal of
Neuroscience Research 31:327-335.

7.

Cornett C, Markesbery W, Ehmann W (1998) Imbalances of trace elements related
to oxidative damage in Alzheimer’s disease brain. Neurotoxicology 19:339-45.

8.

Corrigan F, Reynolds G, Ward N (1991) Reductions of zinc and selenium in brain in
Alzheimer’s disease. Trace Elements in Medicine 8:1-5.

9.

Corrigan F (1993) Hippocampal tin, aluminum and zinc in Alzheimer’s disease.
BioMetals 6:149-54.

10. Crapper McLachlan D, Dalton A, Kruck T, et al (1991) Intramusclar
desferrioxamine in patients with Alzheimer’s disease. Lancet 337:1304-8.
11. Cullen K, Kocsi Z, Stone J (2005) Pericappillary haem-rich deposits: evidence for
microhemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab
25:1656-67.
12. Cullen K, Kocsi Z, Stone J (2006) Microvascular pathology in the aging human
brain: evidence that senile plaques are sites of microhemorrhages. Neurobiol Aging
27:1786-96.
13. Dedman D, Treffry A, Candy J, et al (1992) Iron and aluminum in relation to brain
ferritin in normal individuals and Alzheimer’s disease and chronic dialysis patients.
Journal of Biochemistry 287:509-14.

90

14. Deibel M, Ehmann W, Markesbery W (1996) Copper, iron and zinc imbalances in
severely degenerated brain regions in Alzheimer’s disease: possible relation to
oxidative stress. Journal of Neurological Science 143:137-42.
15. Dhenain M, Privat N, Duyckaerts C, Jacob R (2002) Senile plaques do not induce
susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed
15:197-203.
16. Domaille D, Que E, Chang CJ (2008) Synthetic fluorescent sensors for studying the
cell biology of metals. Nature Chem Biol 4:168-75.
17. El Meskini R, Crabtree K, Cline L, et al (2007) ATP7A (Menkes protein) functions
in axonal targeting and synaptogenesis. Mol Cell Neurosci 34:409-21.
18. Finney L, Chishti Y, Kharet T, et al (2010) Imaging metals in proteins by combining
electrophoresis with rapid x-ray fluorescence mapping. ACS Chem Biol 5:577-87.
19. Florczyk U, Jozkowicz A, Dulak J (2008) Biliverdin reductase: new features of an
old enzyme and its potential therapeutic significance. Pharm Reports 60:38-48.
20. Friedlich A, Lee J, van Groen T, et al (2004) Neuronal zinc exchange with the blood
vessel wall promotes cerebral amyloid angiopathy in an animal model of
Alzheimer’s disease. J Neurosci 24:3453-9.
21. Goodman L (1953) Alzheimer’s disease; a clinico-pathologic analysis of 23 cases
with a theory on pathogenesis. J Nerv Ment Dis 118:97-130.
22. Greenberg S, Vonsattel JP (1997) Diagnosis of cerebral amyloid angiopathy. Stroke
28:1418–1422.
23. Griffiths P, Crossman A (1993) Distribution of iron in the basal ganglia and
neocortex in postmortem tissue in Parkinson’s disease and Alzheimer’s disease.
Dementia 4:61-5.
24. Hallgren B, Sourander P (1958) The effect of age on the non-haemin iron in the
human brain J Neurochem 3:41-51.
25. Hallgren B, Sourander P (1960) The non-haemin iron in the cerebral cortex of
Alzheimer’s disease. J Neurochem 5:307-10.
26. Huang X, Moir R, Tanzi R, et al (2004) Redox-active metals, oxidative stress and
Alzheimer’s disease pathology. Ann NY Acad Sci 1012:153-63.
27. Jellinger K (2010) Prevalence and impact of cerebrovascular lesions in Alzheimer’s
and Lewy Body diseases. Neurodegener Dis 7:112-115.

91

28. Lannfelt L, Blennow K, Zetterberg H, et al (2008) Safety, efficacy and biomarker
findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease;
a phase IIa, double blind randomized placebo controlled trial. Lancet Neurol 7:77986.
29. Leipuviene R, Theil E (2007) The family of iron responsive RNA structures
regulated by changes in cellular iron and oxygen. Cell Mol Life Sci 64:2945-55.
30. Leite R, Jacob-Filho W, Saiki M, et al (2008) Determination of trace elements in
human brain tissue using neutron activation analysis. Journal of Radioanalytical and
Nuclear Chemistry 278:581-4.
31. Lerner-Marmarosh N, Shen J, Torno M, et al (2005) Human biliverdin reductase: a
member of the insulin receptor substrate family with serine/threonine/tyrosine kinase
activity. Proc Natl Acad Sci 102:7109-14.
32. Loeffler D, Connor J, Juneau P, et al (1995) Transferrin and iron in normal,
Alzheimer’s disease and Parkinson’s disease brain regions. Journal of
Neurochemistry 65:710-6.
33. Lovell M, Robertson J, Teesdale W, et al (1998) Copper, iron and zinc in
Alzheimer’s disease senile plaques. Journal of Neurological Science 158:47-52.
34. Magaki S, Raghavan R, Mueller C, et al (2007) Iron, copper and iron regulatory
protein 2 in Alzheimer’s disease and related dementia. Neuroscience Letters 418:726.
35. Markesbery W (1984) Brain trace elements concentrations in aging. Neurobiol
Aging 5:19-28.
36. Miller E, Zeng L, Domaille W, Chang C (2006) Preparation and Use of
Coppersensor-1, a Synthetic Fluorophore for Live-Cell Copper Imaging. Nature
Protocols 1:824-827.
37. Molina-Holgado F, Gaeta H, Williams R, Francis P (2007) Metals ions and
neurodegeneration. Biometals 20:639-54.
38. Panayi A, Spyrou N, Iverson B, et al (2002) Determination of cadmium and zinc in
Alzheimer’s brain tissue using inductively coupled plasma mass spectrometry.
Journal of Neurological Science 195:1-10.
39. Panayi A, Spyrou N, Part P (2001) Differences in trace element concentrations
between Alzheimer and “normal” human brain tissue using instrumental neutron
activation analysis. Journal of Radioanalytic and Nuclear Chemistry 249:437-41.

92

34. Plantin L, Lying-Tunell U, Kristensson K (1987) Trace elements in the human
central nervous system studied with neutron activation analysis. Biological Trace
Element Research 13:69-75.
41. Prohaska J, Gybina A (2004) Intracellular copper transport in mammals. J Nutrition
134:1003-6.
42. Religa D, Strozyk D, Cherny R, et al (2006) Elevated cortical zinc in Alzheimer’s
disease. Neurology 67:69-75.
43. Rogers J, Bush A, Cho H, et al (2008) Iron and the translation of the amyloid
precursor protein (APP) and ferritin mRNAs: riboregulation against neurol oxidative
damage in Alzheimer’s disease. Biochem Soc Trans 36(Pt6):1282-7.
44. Rottkamp C, Raina A, Zhu X, et al (2001) Redox-active iron mediates amyloid-beta
toxicity. Free Radic Biol Med 30:447-50.
45. Schrag M, Dickson A, Jiffry A, et al (2010) The effect of formalin fixation on the
levels of brain transition metals in archived samples. BioMetals in press.
46. Schrag M, McAuley G, Pomakian J, et al (2010) Correlation of hypointesities in
susceptibility-weighted images to tissue histology in dementia patients with cerebral
amyloid angiopathy: a post-mortem MRI study. Acta Neuropathol 119:291-302.
47. Smith DG, Cappai R, Barnham KJ (2007) The redox chemistry of the Alzheimer’s
disease amyloid beta peptide. Biochim Biophys Acta 1768:1976-90.
48. Smith M, Harris P, Sayre L, Perry G (1997) Iron accumulation in Alzheimer disease
is a source of redox-generated free radicals. Proc Natl Acad Sci 94:9866-8.
49. Smith MA, Wehr K, Harris P, et al (1998) Abnormal localization of iron regulatory
protein in Alzheimer’s disease. Brain Res 788:232-6.
50. Stedman J, Spyrou N (1997) Elemental analysis of the frontal lobe of “normal” brain
tissue and that affected by Alzheimer’s disease. Journal of Radioanalytical and
Nuclear Chemistry 217:163-6.
51. Squitti R, Rossini P, Casseta E, et al (2002) D-penicillamine reduces serum
oxidative stress in Alzheimer’s disease patients. Eur J Clin Invest 32:51-9.
52. Tandon L, Ni B, Ding X, et al (1994) RNAA for arsenic, cadmium, copper and
molybdenum in CNS tissue from subjects with age-related neurodegenerative
diseases. Journal of Radioanalytical and Nuclear Chemistry 179:331-9.

93

53. Tokuda E, Okawa E, Ono S (2009) Dysregulation of intracellular copper trafficking
pathway in a mouse model of mutant copper/zinc superoxide dismutase-linked
familial amyotrophic lateral sclerosis. J Neurochem 111:181-91.
54. Vinters HV (1987) Cerebral amyloid angiopathy: a critical review. Stroke 18:31126.
55. Vinters HV, Wang Z, Secor D (1996) Brain parenchymal and microvascular amyloid
in Alzheimer’s disease. Brain Pathol 6:179-95.
56. Vinters HV, Vonsattel JP (2000) Neuropathologic features and grading of
Alzheimer-related and sporadic CAA. In: Verbeek MM, de Wall RMW, Vinters HV,
editors. Cerebral amyloid angiopathy in Alzheimer’s disease and related disorders.
Dordrecht, the Netherlands; Kluwer Academic: pp. 137–155.
57. Ward N, Mason J (1987) Neutron activation analysis techniques for identifying
elemental status in Alzheimer’s disease. Journal of Radioanalytical and Nuclear
Chemistry 113:515-526.
58. Yang L, McRae R, Henary M, et al (2005) Imaging of the intracellular topography
of copper with a fluorescent sensor and by synchrotron x-ray fluorescence
microscopy. Proc Natl Acad Sci 102:11179-84.
59. Zeng L, Miller E, Pralle A, et al (2006) A selective turn-on fluorescent sensor for
imaging copper in living cells. J Am Chem Soc 128:10-1.

94

CHAPTER 5
CORRELATION OF HYPOINTENSITIES IN SUSCEPTIBILITY
WEIGHTED MAGNETIC RESONANCE IMAGES TO TISSUE HISTOLOGY
IN DEMENTIA PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY

Matthew Schrag¹, Grant McAuley¹, Justine Pomakian², Claudius Mueller1,3, Harry V.
Vinters², E. Mark Haacke4,5,6, Barbara Holshouser4, Daniel Kido4, and Wolff Kirsch¹
¹Neurosurgery Center for Research; Loma Linda University, Loma Linda, California
2
Department of Pathology and Laboratory Medicine and Department of Neurology, David Geffen School
of Medicine at the University of California Los Angeles, Los Angeles, California
3
Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
4
The Magnetic Resonance Imaging Institute for Biomedical Research, Detroit, Michigan
5
Department of Radiology; Loma Linda University School of Medicine, Loma Linda, California
6
Department of Radiology; Wayne State University, Detroit, Michigan

Abstract
Neuroimaging with iron-sensitive MR sequences (gradient echo T2* (GRE-T2*)
and susceptibility weighted imaging (SWI)) identifies small signal voids that are
suspected brain microbleeds (BMB). Though the clinical significance of these lesions
remains uncertain, their distribution and prevalence correlates with cerebral amyloid
angiopathy (CAA), hypertension, smoking, and cognitive deficits. Investigation of the
pathologies that produce signal voids is necessary to properly interpret these imaging
findings. We conducted a systematic correlation of SWI identified hypointensities to
tissue pathology in post mortem brains with AD and varying degrees of CAA. Autopsied
brains from eight Alzheimer’s disease patients, six of which showed advanced CAA,
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were imaged at 3T; foci corresponding to hypointensities were identified and studied
histologically. A variety of lesions was detected; the most common lesions were acute
microhemorrhage, hemosiderin residua of old hemorrhages, and small lacunes ringed by
hemosiderin. In lesions where the bleeding vessel could be identified, ß-amyloid
immunohistochemistry confirmed the presence of ß-amyloid in the vessel wall.
Significant cellular apoptosis was noted in the perifocal region of recent bleeds along
with heme oxygenase 1 activity and late complement activation. Acutely extravasated
blood and hemosiderin were noted to migrate through enlarged Virchow-Robin spaces
propagating an inflammatory reaction along the local microvasculature – a mechanism
that may contribute to the formation of lacunar infarcts. Correlation of imaging findings
to tissue pathology in our cases indicates that a variety of CAA related pathologies
produce MR-identified signal voids and further supports the use of SWI as a biomarker
for this disease.

Introduction
In vivo evidence of cerebral amyloid angiopathy (CAA) was limited until the
introduction of gradient echo T2* (GRE-T2*) weighted magnetic resonance (MR)
imaging, which remains the clinical standard for detection of brain microbleeds (BMB)
which often result from CAA (Atlas 1988). BMB are detected as focal signal intensity
losses, presumably secondary to iron-containing hemosiderin residua of hemoglobin
breakdown. Though recent reviews of the BMB literature have attempted to codify the
interpretation of these findings, the inconsistency of data sets, the lack of pathological
confirmation and the need for better designed prospective studies to determine their
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clinical significance has been emphasized (Viswanathan 2006, Cordonnier 2007a,
2007b). Detection of BMB is improved by new, high-resolution, 3D GRE-T2* and
susceptibility weighted imaging (SWI). SWI is an advance in T2* weighted brain MR
imaging that enhances contrast from local susceptibility tissue variations (Haacke 2004,
2005). At 1.5T, the SWI sequence was found to be four fold more sensitive for detection
of traumatic BMB than conventional GRE-T2* and recent data in MCI subjects indicates
again at least a four fold increase in BMB recognition by SWI compared to conventional
GRE-T2* imaging (Tong 2003, 2004, Sehgal 2005, Haacke 2007).
To date, punctate signal voids have been observed in a number of diseases – by
far the most common are hypertension and CAA. Those associated with hypertensive
vasculopathy tend to be localized to basal ganglia, internal capsule, brain stem, and
cerebellum, whereas those associated with CAA are generally smaller with a posterior
lobar predilection (Walker 2004, Rosand 2005). CAA is comorbid with Alzheimer’s
disease (AD) in as many as 95% of AD cases (Jellinger 2007). In this condition the βamyloid peptide is deposited along the cerebral and meningeal vasculature in the walls of
small and medium-sized arterioles. This peptide appears to induce a local inflammatory
response ranging from subtle changes to, in extreme cases, a granulomatous angiitis with
apoptotic death of vascular smooth muscle cells (Aliev 2002, Anders 1997). Studies of
CAA autopsy material have confirmed these findings and the presence of other (non-βamyloid) proteins such as cysteine protease inhibitor (cystatin) in CAA vessel walls
(Anders 1997). Vascular wall infiltration with these proteins appears to be associated
with a structural instability of arterioles accounting for BMB and associated MR signal
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voids; however, the biologic and molecular mechanisms for β-amyloid accumulation,
inflammatory and oxidative responses, and vascular weakening are unclear at present.
Recent evidence has shown that the presence of BMB predicts reduced global
cognitive function and is a risk factor for progression of mild cognitive impairment to
outright dementia (Yakishiji 2008, Kirsch 2009). Additionally, one study noted a
significant correlation between patients with at least one hypointensity in GRE-T2*
imaging and those homozygous for the Apolipoprotein E ε4 gene, a well-known risk
factor for Alzheimer’s disease (Sveinbjornsdottir 2008). Remarkably, there have been
very few verifications of the histopathology of radiologically identified BMB, and none
utilizing the newer sensitive sequences (Cordonnier 2007a). There are currently three
reports in the published literature that describe the pathology of hypointensities in MR
images; all three rely upon GRE-T2* imaging and most evaluate hypertensive patients.
A recent case report isolated eight microbleeds from a single, elderly hypertensive
patient (Tatsumi 2008). Tanaka and colleagues studied hypointensities in three relatively
young autopsy cases, two involving hypertension and one a large mass in the brain
indicating that hemosiderin granules were found corresponding to hypointensities, except
in one case where a microaneurysm was found (1999). The largest correlative study
evaluated eleven cases, but was only able to correlate imaging findings to pathologic
abnormalities in six. The hypointensities in that study were associated with hematomas
and/or hemosiderin granules. However, only two of the cases had CAA and one of them
was also hypertensive; neither of the patients was identified as having been clinically
demented during life (Fazekas 1999).
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More recently, SWI has been used to study trauma; in this venue, numerous
papers have shown SWI to be particularly sensitive for detecting blood products (Tong
2003, 2004). Still, none of the many works in this area have correlated the imaging
findings seen in trauma with histology. Our study represents the first correlation of SWI
focal hypointensities to tissue pathology in post mortem human CAA-affected brain.

Materials and Methods
Patient Characteristics
Post-mortem tissue was obtained from the Alzheimer’s Disease Research Center
Brain Bank at the University of California, Los Angeles (Harry V. Vinters). All patients
or their surrogates had consented to participate in research protocols prior to tissue
donation. The research protocol was approved by the Institutional Review Board of
Loma Linda University Medical Center (approval #54174). The average age of
participants was 79.9 years with a standard deviation of 9.3 years; four were male, four
female. All patients had long clinical histories of dementia. AD pathology was classified
by Braak and Braak staging guidelines and CAA pathology was graded by Vonsattel’s
criteria. Briefly, grade 1 CAA involves ß-amyloid deposition primarily in a fine rim on
the basement membrane. Grade 2 disease extends to allocortical and cerebellar vessels
and deposition of ß-amyloid among smooth muscle cells partially replacing the tunica
media. Grade 3 disease involves total replacement of arteriolar vascular smooth muscle
(Greenberg 1997). Autopsy findings confirmed Braak and Braak pathology at stage VI
and Vonsattel pathology at grade 3 for four of the brains. Two cases were found to have
severe CAA pathology (grade 3) out of proportion to AD pathology. These are included
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as relatively “pure” cases of CAA. Two had stage VI AD pathology, but negligible CAA
– these were included as AD controls. In addition to the eight demented cases, two
neurologically normal, aged control brains were scanned along with the others and no
hypointensities were detected in them. One of the patients with severe CAA and AD died
of an acute intracerebral hemorrhage; the affected lobe was excluded from analysis.
None of the patients had a history of hypertension, traumatic brain injury or other causes
of BMB. Cases with Lewy bodies detected on pathologic examination were excluded.
Patient demographics, clinical duration of dementia (when known) and the imaging
findings are listed in Table 8.

Tissue Preparation
Three, 1cm coronal sections were obtained from each of eight human brains at
autopsy; slices were taken through the frontal, temporo-parietal and occipital lobes.
Because lesions frequently occur near the periphery of tissue specimens in CAA, they are
easily obscured in post-mortem imaging by the artifact produced at the air-tissue
interface. To eliminate this interface and movement artifacts in imaging and to improve
the ease of handling delicate tissue, the formalin fixed brain slices were embedded in
blocks of 4% agarose gel. Agarose is an aqueous suspension that effectively contrasts to
the fixed tissue in MR images and eliminates the phase disturbance. The encased tissue
is well-preserved, and the gel block is easier to orient within the MR scanner and
eliminates tissue movement, which was encountered when specimens were imaged in
liquids. Agarose did not penetrate the tissue and was neatly separated from the specimen
after imaging was completed. Air bubbles mimic the signal voids of focal iron, so care
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TABLE 8: Patient demographics and locations of microbleeds on MR
Case#
age/sex
1. 89/M
2. 81/M
3. 61/M
4. 85/F
5. 73/F
6. 90/M
7. 74/F

8. 86/F

Clinical severity
of dementia
14 yrs / severe
Severe / slow
progression
2 yrs / rapid
progression
Slow progression

B&B*/
Vonsattel grade
VI / 0
VI / 0

Lesion locations
Cortical
Deep grey
White
grey matter
matter
matter

-

-

-

-

-

-

IV / 3+

1

-

4

V / 3+

-

1

4

Severe
Severe / slow
progression
Severe / slow
progression

VI / 3
VI / 3

-

1

3
4

VI / 3

7

2

2

8 yrs / slow
progression

VI / 3

4

1

4

*B&B=Braak and Braak score
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Cause of death
Pneumonia
Pneumonia
Complications of
malnutrition
Coronary artery
disease
Unknown
Emphysema/pne
umonia
Massive
intracerebral
hemorrhage in
the right
frontal/parietal
lobes
Pneumonia

was taken to thoroughly remove any bubbles which might complicate interpretation of
the MR scans.
Imaging Parameters
MR imaging was performed on a 3T scanner in the coronal plane (Siemens). The
following parameters were used: echo time, 20ms; repetition time, 30ms; flip angle, 15°;
slice thickness, 2mm; matrix size 256mmx256mm; in plane resolution, 0.5mmx0.5mm.
The images were reviewed by two experienced interpreters blinded to autopsy diagnoses
and any conflicts were settled by the senior neuroradiologist at Loma Linda University
Medical Center, Dr. Daniel Kido. An explanation of hypointensity reporting criteria has
been published previously and is comparable to other established protocols (Kirsch 2009,
Cordonnier 2008). Briefly, hypointensities were identified as regions 5.7 mm or less in
diameter of relative signal void (Greenberg 2009). Additionally, hypointensities were
evaluated for continuity with blood vessels, and location within a sulcus. If either were
present, the hypointensity was interpreted as vascular in origin or an artifact from an air
bubble and was not counted.

Dissection and Histology
The focal points of interest were located within the tissue block by orienting to
tissue architecture and cutting at the depth estimated from the slice thickness of the MR
images, thus enabling accurate dissection and consistent recovery of the lesion. Thirteen,
well-dissected microbleeds, 5 cortical and 8 at the grey-white junction with at least one
specimen from each CAA case, were measured with precision calipers through the widest
point to record their diameters for comparison to apparent size in the MR images.
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For immunohistochemistry, markers were observed on adjacent sections for each
of ten histological specimens -- representing two acute bleeds with intact erythrocytes,
five old hematomas, two cavitary specimens and one bleed in the basal ganglia. These
specimens were embedded in paraffin in the usual fashion. Serial sections were cut at a
thickness of 8 μm through the region of interest and mounted on slides for hematoxylin
and eosin staining, immunohistochemical and fluorescent studies. The sections were
deparaffinized in three exchanges of xylene, rehydrated through serial alcohol exchanges,
and permeabilized in 0.01% TritonX in PBS. Antigen retrieval was performed by heating
sections in a microwave three times for three minutes each while submerged in a 0.01%
citrate solution. The sections were then treated with 1% hydrogen peroxide in PBS and
incubated with a blocking solution of 1.5% normal serum (also in PBS). Sections were
then incubated with the primary antibody of choice in 4% normal serum overnight at 4°C.
After washing with PBS, sections were incubated with the secondary antibody for two
hours, washed in additional exchanges of PBS and treated with diaminobenzidine/
hydrogen peroxide (DAB) for ten minutes (Vector Laboratories). They were then rinsed
for 3 min in PBS, dehydrated through serial alcohols, cleared to xylene and coverslipped
with mounting resin (Permount, Fisher). Antibodies used were those against Aβ1-42
(1:100, Abcam), CD68 (1:100, Dako), HO-1 (1:250, Biomol) and complement C6 (1:500,
Quidel).
For visualizing iron, sections were stained by the enhanced Prussian Blue method
by immersing the sections in a mixture of equal parts of 20% hydrochloric acid and 10%
potassium ferrocyanide solution for 20 min. All sections were washed in 3 changes of
distilled water and incubated with DAB (Vector Laboratories). They were counterstained
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with hematoxylin for 5 min, rinsed twice in distilled water, and dehydrated through 95%
and 100% alcohol. Slides were cleared in xylene, and mounted with resinous mounting
medium.
Fluorescent studies were performed on four microbleed specimens -- two acute
bleeds and two old hematomas. In order to more thoroughly characterize heme
oxygenase 1 (HO-1) levels around lesions, we double labeled sections for HO-1 and
MAP-2, a marker of neurons. Sections (8 μm) cut through the lesion were deparaffinized
in 3 changes of xylene and washed in PBS for 15 min. They were then treated with 0.3%
hydrogen peroxide in methanol for 30 min and incubated with a blocking solution of 2%
normal goat serum in PBS. Subsequently, sections were incubated overnight at 4°C with
mAb to HO-1 (1: 100, BioMol) followed with FITC-conjugated goat anti-mouse
secondary antibody (1: 500) for 30 min at room temperature. After three 5 min rinses in
PBS, sections were blocked with 5% normal mouse serum. After 2 h incubation with
MAP-2 monoclonal antibody (1: 500, Abcam) sections were rinsed three times in PBS
for 5 min each and incubated with Texas Red conjugated goat anti-mouse secondary
antibody in PBS for 30 min temperature. Sections were then rinsed in PBS, coverslipped
with Vectashield containing DAPI (Vector Laboratories) and observed under a confocal
microscope (Olympus). Apoptosis detection was performed using the terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique
(Vector Laboratories). Five fields at a magnification of 100 × were captured adjacent to
each lesion and compared to fields at least five diameters away from the lesion.
Statistically significant differences were determined by the Student t-test.
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Results
Radiologic-histopathologic Correlation
Thirty-eight lesions were detected in SWI images from our cases (Fig.8 and Table
8). The lesions ranged from 0.5 to 5 mm in diameter, and in ten lesions intact
erythrocytes were found. In sixteen specimens, old hematomas were found which
contained dark brown cellular debris positive for Prussian Blue staining. In seven of the
specimens, small cavities were found at the site indicated by the MR image. At three
sites, no pathology was visible on gross inspection, but hemosiderin granules and
hematoiden deposition were detected at microscopy. At one site a dissection in the wall
of a grossly distended vessel was discovered and blood within the vessel wall apparently
produced the hypointensity on SWI. One additional hypointensity was caused by a
microaneurysm (Fig. 9). The vast majority of lesions (79%) appeared near the cortical
ribbon in two key distributions – just beneath the grey-white junction (eighteen lesions,
recorded in Table 8 as white matter lesions) and in the superficial cortex where pial
arterioles penetrate the grey matter (twelve lesions). Representative examples of each are
present in the adjacent lesions in Figure 8a-c. Deep white matter lesions were rarely
observed (three of the thirty-eight total specimens) and all had an atypical cavitary
appearance.
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Figure 8: Correlation of hypointensities and tissue pathology
The stepwise isolation of two lesions is illustrated above. In image A, a hypointensity in
SWI is noted in the left temporal lobe (scale bar = 5mm). The corresponding lesion is
shown in image B. This hematoma is typical of those located in grey matter, the blood
does not diffuse into the tissue, but remains encapsulated within a pseudocapsule (scale
bar =1mm). A second lesion is present in this tissue block; the size of this lesion is
overestimated by SWI, illustrating the “blooming effect” of this technology (arrowheads
in a & b). Another hypointesity located in the white matter of the left parietal lobe is
indicated in image D (scale is equal to image A). The corresponding lesion has been
dissected in image E and is shown under a dissecting microscope in image F. The final
image shows a cavitary lesion trabeculated by vascular elements. Further histologic
workup of the lesion demonstrated hemosiderin granules within a gliotic capsule (see Fig.
13).
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Figure 9: MR hypointensities without grossly visible pathology
The vast majority of hypointensities were associated with hemorrhages visible upon
dissection; however a few required more extensive investigation. Shown in image A is a
well-healed lesion consisting of focal scarring with hemosiderin deposits stained by DAB
enhanced Prussian Blue stain. Hematoiden deposition is also noted in the lesion (white
arrow). Image B shows an arteriolar aneurysm (white arrows indicate the dome of the
aneurysm; black arrow indicates the “parent” artery). Image C shows a severely dilated
vessel with a dissection in the endothelium and blood in the vessel wall (arrows point the
ruptured endothelial layer).
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Figure 10: The “blooming effect” of signal voids induced by hemosiderin-iron
The theoretical equality of lesion size to MR hypointensity size is graphed in red. The
actual measurements are shown in the scatter plot and almost all the lesions are smaller
than their associated MR finding. The signal voids averaged 1.58+/-0.75 times the size
of the associated lesion.
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Figure 10 compares the size of lesions to their apparent size in SWI. SWI
consistently over-estimated the diameter of small lesions in what has previously been
termed the “blooming effect;” hypointensities in this study were 1.57+/- 0.75 times the
size of the corresponding lesion. This discrepancy was most notable with smaller lesions
where the hypointensity could appear more than three times the diameter of the actual
lesion. This effect is illustrated in images A and B of Figure 8 which show one lesion
which appeared nearly accurately sized on SWI and another which was significantly
magnified by the MR image. This effect may make quantifying the volume of
hemorrhage from these MR images unreliable for BMB on the order of the voxel size.

CAA-Related Vascular Damage
In several hemorrhages it was possible to determine which vessel ruptured. In
these cases specific observation of the underlying vascular pathology was possible. We
also examined the vasculature near sites of hemorrhage when examination of the ruptured
vessel was not possible. ß-amyloid immunostaining demonstrated that ß-amyloid
deposition was present in the walls of involved vessels. Hematoxylin and eosin staining
revealed significant morphologic changes in vessels associated with hemorrhage and the
surrounding arterioles. The vessel walls were noted to be thickened, profoundly
acellular, and lacking evidence of a musclaris layer. The pathology primarily involved
arterioles, capillaries were only sparsely affected.
CD68 immunostaining revealed activated microglia or macrophages on nearly all
of the larger parenchymal vessels in a cortical/subcortical distribution. Little vascular
staining was present in the deep grey matter. Complement activation on vessels was
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assessed with an antibody against complement component C6, the first component of the
membrane attack complex (MAC) that stably inserts into the cell membrane. Once C6 is
bound to C5b in the cell membrane, the MAC is activated, inevitably leading to cell
lysis. The arterioles in CAA brain stained intensely against the C6 marker. This staining
was associated with evidence of medial intima degeneration – the characteristic targetshaped vessel morphology associated with severe CAA. Arterioles in the basal ganglia
did not react with the C6 antibody.

Evidence of Peri-Hematoma Inflammation
Evidence for the presence of heme oxygenase 1, an inducible, pro-oxidative
enzyme that catalyzes the degradation of heme into biliverdin, carbon monoxide and free
iron, was noted around many hematomas in the form of hematoiden, a bright yellow
pigment. This pigment intensely stained the injured vessels in numerous lesions as
illustrated in Figure 11. Representative microbleeds were evaluated with
immunohistochemical staining against HO-1. Intense staining of the hematoma was
noted in every case along with variable reactivity of the adjacent parenchyma. More
prominent staining of this adjacent tissue was noted near recent bleeds; however, some
HO-1 activity was noted even around old bleeds without evidence of intact erythrocytes.
With fluorescent staining against HO-1, numerous non-neuronal cells in the
perihematomal region stained strongly positive for HO-1 around both old and recent
hematomas. No heme oxygenase activity was noted around the cavitary lesions. CD68
is a marker for cells of monocyte lineage and will stain microglia, macrophages and
neutrophils. While intense reactivity of this antibody was noted in the vessels associated
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with each lesion, acute bleeds stained less intensely than old hematomas. Old hematomas
were stained throughout the lesions and in perivascular spaces in which hemosiderin was
deposited. Finally, TUNEL staining for apoptotic cells was undertaken on four of the
lesions (images not shown). Because formalin archived tissue was used in this study,
significant auto-fluorescence was present in the sections. To be considered apoptotic, a
cell had to be both marked with the TUNEL probe and demonstrate a pyknotic or
fragmented nucleus by DAPI staining. The region immediately adjacent to the hematoma
was noted to contain significantly more apoptotic cells than the background -- a nearly
four-fold increase. The apoptosis rate in the background tissue of severe CAA/AD
patients was 0.93% (+/- .39%); 3.9% (+/- 1.6%) of the cells adjacent to the hematomas
met criteria for apoptosis (p<0.01).

Formation of Secondary Ischemia and White Matter Lesions
Cavitary, lacune-like lesions were present in one of seven deep grey matter lesions
(14%), and six of twenty-one white matter lesions (29%). Three of these lesions occurred
in deep white matter, three were in subcortical white matter. These sites were ringed by
scarred vascular elements and a gliotic capsule containing hemosiderin granules.
Cavitary lesions in the deep white matter were larger (3-5mm in diameter) than the
subcortical cavitary lesions (1-2mm). Several additional lacunar infarcts and numerous
microinfarcts were encountered in the tissue which did not appear on SWI as
hypointensities.
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Figure 11: Vascular damage associated with CAA and hemorrhage
Images A shows the vessel associated with the lesion in Figure 7c. The vessel wall is
hypocellular, eosinophilic and is surrounded by prominent macrophages. The arteriole is
stained a brilliant yellow by the endogenous pigment hematoiden (a breakdown product
of biliverdin indicating the presence of heme oxygenase activity). Image B represents an
immunohistochemical stain of the same vessel demonstrating the presence of ß-amyloid
1-42 in the vessel wall. Image C represents an immunohistochemical stain against CD68,
a marker of macrophages and microglia, demonstrating intense microglial activation
around vascular elements and macrophages in the vessel wall. Image D shows
immunohistochemistry for complement C6. The microvessels in CAA stain strongly for
C6 in the tunica media.
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Figure 12: The local tissue reaction
Immunhistochemical staining highlights the local inflammatory response produced by a
hematoma. Image A is stained by DAB over an anti-HO1 primary antibody and
illustrates intense HO-1 reactivity within a hematoma and extending into the surrounding
parenchyma (H indicates hematoma). Image B is a merged fluorescent study with
MAP2/TexasRed staining in red to mark neurons, DAPI in blue to mark all cell nuclei
and anti-HO1/FITC in green showing the presence of heme oxygenase 1; the hematoma
is visible in the inferior portion of the photo as non-specific staining (again labeled H).
Perinuclear HO-1 expression is noted in the peri-focal zone in non-neuronal cells. Image
C shows CD68 reactivity indicating a prominent microglial response around a vessel and
hemosiderin deposition mainly in macrophages in the vessel wall. H&E of an adjacent
section of the identical vessel is shown in image D with perivascular heme-degradation
products (arrows).
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Figure 13: Perivascular hemosiderin deposition may contribute to subsequent
ischemic changes. Image A shows a hemorrhage around a degenerated arteriole with
hematoiden deposition (yellow/orange material), significant local inflammation and
hemosiderin both in the lesion and tracking in the perivascular space along the arteriole
(white arrow). Image B shows another vessel, ~500 microns distant from the lesion in
image A, with extensive perivascular hemosiderin (arrow). Hemosiderin was present
around both capillaries and arterioles at a distance of more than twice the diameter of the
lesion and was accompanied by inflammatory cells. Image C shows another lesion that
appeared as a hypointensity in SWI (the cavitary lesion shown in Fig. 8d,e,f) and on
pathological examination proved to be a lacunar infarct. Image D shows in detail the
vessels indicated by the arrow in image C. These vessels are also surrounded by
numerous inflammatory cells and macrophages interspersed with hemosiderin granules
(arrows).
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In acute bleeds in the white matter, hemorrhage products were noted to seep into
the surrounding tissue whereas hematomas discovered in grey matter were generally
well-circumscribed lesions surrounding an injured vessel. Blood was noted to propagate
along perivascular spaces away from the hemorrhage, bathing the regional vessels in
blood and blood degradation products. These vessels were surrounded by small,
basophilic immune cells and numerous macrophages/activated microglia (Fig. 13).
Similar pathologic abnormalities were found around the larger vascular components
entering sites of ischemic cavitary lesions. No intact erythrocytes or evidence of acute
blood was detected in or near any of the cavitary lesions. However, granular hemosiderin
deposits and hemosiderin-laden macrophages were noted in the gliotic capsule around the
lesion, so the lesions were interpreted as old, healed hemorrhage sites. Vessels were
noted to cross nearly all of the cavitary lesions, but they appeared scarred, emerged from
a fibrotic matrix and contained no residual blood suggesting a possible secondary
ischemic pathology contributing to the appearance of the lesions. (See Fig. 13)

Discussion
Post mortem MRI is valuable both as a research method and in clinical pathology
(Nicholl 2007). Several approaches to post-mortem MR imaging have been utilized,
from scanning native, unfixed tissue to scanning fixed tissues bathed in liquid to
embedding tissues in gels (Fazekas 1999, Schmierer 2007). Embedding tissues improves
control and quality of the images and protects and preserves the specimens (Pfefferbaum
2004). As neuroimaging techniques advance, it is important that imaging findings are
carefully correlated to tissue pathology. Post mortem imaging enables a definitive

121

approach to this process. While fixation of the brain certainly alters its magnetic
resonance properties, these changes have been well-studied and can be accommodated
within standard imaging protocols (Carvlin 1989, Blamire 1999). The architecture of the
brains in our study remains clearly visualized with good signal-to-noise ratio at the
current parameters. Moreover, iron pools have been shown to be stably preserved in
formalin-archived tissue, so it is unlikely that the lesions of interest in this study were
compromised by the fixation process (Bush 1995).
In this study, blood and/or hemosiderin was encountered corresponding to every
signal void in susceptibility weighted images, but the size of the signal void did not
reflect closely the size of the hemorrhage. There is wide variation in BMB size, location,
and presumed clinical significance. Very small BMB with diameters of 50-200 μm are
widespread in the AD brain, but BMB visible by 1.5T GRE-T2* range from 3-10 mm in
diameter in the MR image (Cullen 2005). There is general agreement among radiologists
that BMB are homogeneous round signal losses with diameters less than 5 mm, though
some reports include lesions up to 10 mm in apparent diameter (Koenncke 2006). A
recent report determined that hemorrhages fall in a bimodal distribution between macro
and microhemorrhages with the critical separating value being 5.7mm (Greenberg 2009).
Those detectable by SWI at 3T in this study are as small as 1mm in apparent diameter on
the scans, and 0.3-0.4 mm measured diameter in the tissue. SWI consistently
overestimated the size of bleeds in what has been termed a “blooming effect.” In our
specimens, the blooming effect magnified the smallest bleeds by as much as 300%.
Because of this phenomenon, the apparent size of the lesion on MR is an unreliable
estimate of the extent of tissue injury.
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The underlying pathologic lesions we discovered correlating to hypointensities
was quite varied. The vessels associated with bleeding demonstrated pathologies
classically associated with CAA including vessel wall thickening, ß-amyloid replacement
of vascular smooth muscle, microaneurysms and, most frequently, frank hemorrhage. ßamyloid has been shown in in vitro studies to be particularly toxic to vascular smooth
muscle cells, which may explain the relative acellularity of the muscularis layer in the
involved arterioles (Davis 1999). Complement activation was also noted as a prominent
part of the vascular pathology, and may be a mechanism of or contribute to amyloid
toxicity in the vessel wall. The presence of late complement component C6 surrounding
diseased vessels and hemorrhages is a notable finding. Numerous studies have examined
the role of the complement system in Alzheimer’s disease; it has been established that
Abeta binds to both C1q and C3 of the classical complement pathway, activating the
early portion of the cascade (Yasojima 1999, Terai 1997). However, the cascade is only
activated through C3 in the tissue parenchyma; the lytic portion has not been noted to
play a major role in the inflammation induced by beta-amyloid plaques (Cadmen 1997).
However, we found that the lytic pathway is observed prominently in the vessel wall.
Cultured human cerebrovascular cells have been shown to secrete all the components of
the late complement cascade and C6 in particular is upregulated in the presence of βamyloid (Walker 2008). The Alzheimer’s brain is primed for a complement reaction;
with elevated parenchymal levels of activated early complement, the introduction of the
terminal proteins through vascular injury and hemorrhage may trigger significant cellular
loss. The presence of activated MAC in this pathology may make this cascade of future
therapeutic interest.
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Several sites thought to be microvascular bleeding on SWI were found to be
associated with cavitary lesions resembling small lacunar infarcts. Iron deposits were
found in the gliotic capsule around these lesions which presumably produced the signal
void appreciated on SWI (Fig. 13c,d). In a few cases, particularly larger lesions, a
hyperintense halo was present around the hypointensity (Fig. 8). A correlation between
microbleeds and lacunar infarcts has been established by a number of imaging studies; in
fact, one recent study found the presence of a lacunar infarct the strongest predictor of
microbleeds in neurologically healthy adults, stronger than all traditional vascular risk
factors (Igase 2009). The cause of this phenomenon is not entirely clear from previous
studies. Central nervous system microvasculopathies are well-associated with lacunar
infarcts, causing a disturbance in the penetrating arteries feeding white matter tracts,
interrupting this important terminal blood supply (Fisher 1991). Recently, the severity of
CAA pathology was shown to correlate with the prevalence of microinfarcts in both grey
and white matter (Soontornniyomkij 2009). Several observations here may help clarify
the pathological mechanism underlying these lesions and why they are so closely
associated with microhemorrhages. The tissue response to microhemorrhage is an
intense inflammatory reaction. We found that a rim of activated microglia forms around
the hemorrhage, complement is activated and HO-1 is induced. This ultimately results in
significantly increased cell death including the loss of neurons about the lesions. It has
been well-described that extracellular fluids in the brain migrate along the vascular bed in
a retrograde fashion through perivascular spaces and are reabsorbed at the level of the
arterioles (Schley 2006). These Virchow-Robin spaces are significantly dilated in CAA
which could facilitate the movement of perivascular contents (Roher 2003). As shown in
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Figure 9, blood from hemorrhagic lesions propagates through the perivascular space
predisposing to an inflammatory reaction along a significant portion of the local
vasculature. This pattern of spread also has been noted in MR studies looking at the
symptomatic perforating artery adjacent to a lacunar infarct (Wardlaw 2001).
Additionally, the toxic milieu is confined differently in white matter and grey matter.
The Virchow-Robin spaces in grey matter are invested with two meningeal membranes,
one basal lamina closely investing the vessel, one investing the glia limitans at the
parenchymal surface. In the white matter, the parenchymal membrane is absent, which
seems to facilitate the migration of hemorrhagic blood products through the white matter,
while it is generally confined to a hematoma in the grey (Pollock 1997). This may result
in a more aggressive inflammatory response in the white matter, increasing the
probability of spasm or scarring of the vascular supply. These features could
conceptually account for the ischemic appearance of some lesions, particularly in the
white matter. We observed significant scarring in vessels surrounded by hemosiderin as
they enter the lacune-like portion of BMB.
This study is an important step in validating the interpretation of hypointensities
in SWI as brain microbleeds. A number of studies now argue in favor of the use of these
signal hypointensities as a biomarker of CAA. This may be justified, but we offer a few
cautions. First, while hypointensities in this study were associated with CAA pathologies
(microbleeding, microaneurysm and endoluminal defect) there are rarely causes for
hypointensities that are unrelated to this pathology, including microthrombi,
calcifications and air emboli. Additionally, while the distribution of lesions in CAA is
characteristic, other disease processes can also produce microhemorrhages. The presence
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of hypointensities should be interpreted in light of the clinical setting and the presence of
a single hypointensity in a normotensive patient who is cognitively normal may be of
little clinical importance (Knudsen 2001). However, the presence of multiple BMBs is
rarely, if ever, benign and likely does represent microvascular bleeding. Detectable
bleeding in a distribution consistent with CAA likely indicates significant additional
bleeding below the threshold currently detectable by clinical imaging studies (Cullen
2005).
BMB are clearly an important “lesion.” Some studies indicate that over 95% of
AD patients are found at autopsy to have some degree of CAA pathology (Greenberg
1997). Roughly one-third of patients with AD have MR detectable microbleeds, and
patients whose cognitive loss is primarily associated with this sort of bleeding may
respond to different sorts of treatment modalities. These lesions have also been noted
early in the process of cognitive loss and have a prognostic value for the progression of
mild cognitive impairment to dementia. When viewed as an ongoing, progressive
process, it is not difficult to believe that CAA and microvascular bleeding play a
significant role in the cognitive dysfunction ascribed to Alzheimer’s disease. Ultimately,
we continue to wait for effective therapeutic strategies for dementia to emerge, but this
imaging technique offers in vivo diagnostic potential to a significant portion of
Alzheimer’s patients and accurate diagnosis is a prelude to therapy.
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CHAPTER 6
CONTINUING STUDY: IS DYNACTIN INVOLVED IN DYSFUNCTION AXONAL
TRANSPORT OF COPPER IN ALZHEIMER’S DISEASE?
Matthew Schrag, Claudius Mueller, Matthew Zabel, Andrew Crofton, Christopher J.
Chang, Wolff Kirsch

Introduction
While copper levels in the human brain are considerably lower than either iron or
zinc, copper may play a central role in numerous neurodegenerative diseases. Alterations
in copper metabolism can have numerous negative effects. For instance, removing the
copper cofactor from super-oxide dismutase reduces its activity, rendering tissues more
sensitive to oxidative stress – a mechanism central to amyotrophic lateral sclerosis (ALS)
pathogenesis (Museth 2009, Hayward 2002); protein disulfide isomerase which is critical
for proper protein folding in the endoplasmic reticulum requires a copper cofactor
(Narindrasorasak 2003); and genetic abnormalities of copper chaperones (Menkes and
Wilson’s diseases) result in severe neurological dysfunction and early death (de Bie
2007). Copper is also bound by prion protein which is associated with Creutfeldt-Jakob
disease, alpha-synuclein in Lewy bodies of Parkinsonian brain and by nearly every
protein associated with Alzheimer’s disease pathology (Wu 2010, Wang 2010, Macreadie
2008). Beta-secretase requires a copper cofactor, amyloid precursor protein binds and
effluxes copper from neurons, and beta-amyloid plaques contain high concentrations of
copper in their cores (Dingwall 2007, Lovell 1997).
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Copper is also physiologically concentrated within synaptic vesicles and is
released into the synaptic cleft in a burst with neurotransmitters. Although we do not
completely understand its effects, this copper burst appears to be functionally important,
inducing alterations in N-methyl D-aspartate (NMDA) receptors and in long-term
potentiation (Leiva 2003, Schlief 2006). Because of our previous observation that copper
in AD brain is depleted, we sought to determine whether copper in synaptic vesicles is
also depleted in AD brain.

Preliminary Findings
From brain homogenate, an enriched fraction containing synaptic vesicles was
isolated by ultracentrifugation as previously described and copper levels (normalized to
protein concentration) were determined by graphite furnace atomic absorption
spectroscopy also described previously (Ohsawa 1975, Schrag 2010). Copper levels
were increased in isolated vesicles 5,000 fold over total brain copper levels (30,000 µg
copper/g synaptic protein, vs 6 µg copper/g total brain protein) (Squitti 2006). Synaptic
vesicles in cases with AD without significant CAA were found to be significantly
depleted of copper compared to vesicles from controls and AD cases with severe CAA –
n=4 in each group. Histological stains of unfixed brain sections with coppersensor 3
(CS3), a sensitive analogue of the CS1 probe used in previous studies, revealed a
remarkable redistribution of copper in AD cases without CAA. The pattern was
essentially unchanged between controls and AD / CAA cases, but in AD without CAA an
intense axonal staining pattern was present. These findings may indicate that there is a
defect in axonal transport or in incorporating copper into vesicles in these cases (Fig. 14).
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Figure 14: Copper levels in enriched synaptic vesicle preparation are significantly
reduced in AD cases without significant CAA involvement (upper panel). CS3 staining
of monovalent copper (lower panel) demonstrates accumulation of copper in the axons in
brain from cases with AD pathology without significant CAA. Copper in synaptic
vesicles is primarily divalent and therefore not visible in the histological images. These
findings suggest there may be an abnormality in axonal trafficking of copper.
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Next, we screened a proteomic database for serum protein changes occurring only
in AD w/o CAA cases. In particular we focused on proteins and protein fragments
related to axonal transport. Plasma was collected from four groups of patients –
neurologic controls, patients with mild cognitive impairment, patients with AD without
radiologic evidence microbleeding (AD only) and AD patients with multiple microbleeds
(AD / CAA) – n=6 in each group. Samples were analyzed with an orbitrap LC/MS/MS
technique as previously described and more than 1500 proteins were identified in the
plasma samples (Mueller 2010). Dynactin sub-unit p62 was found to be significantly
higher in plasma from AD patients without evidence of CAA (Fig. 15). Additionally, we
assessed the levels of dynactin in the post-mortem brain by western blot. Dynactin was
significantly reduced in the AD only group compared to both controls and AD/CAA,
p=0.01.

Future Directions
The interaction between dynein and dynactin has previously been reported to
decline with aging; moverover, reducing the expression of dynactin by siRNA in a cell
culture system was found to increase both amyloid precursor protein (APP) levels and
beta-cleavage of APP and also resulted in axonal accumulation of tau (Kimura 2007,
2009). Curiously, the p62 subunit of dynactin (the subunit found increased in plasma and
decreased in brain from cases with AD without CAA) was found to binding ATP7b – a
major copper chaperone (Lim 2006). Dynactin is a conceptual link between copper
trafficking and axonal transport mechanisms. While the proteomic and post-mortem data
support the hypothesis that lower p62 levels result in axonal trapping of copper and
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Figure 15: Plasma collected from neurologically normal patients was compared to
plasma from those with mild cognitive impairment, AD without radiologic evidence of
microbleeds and AD with multiple microbleeds (upper panel). The p62 subunit of
dynactin was found to be significantly elevated in the AD only group and was
undetectable in all of the control cases. Western blot analysis of p62 levels in the brain in
comparable groups demonstrated the opposite pattern – p62 levels are significantly
lowered in the AD only group compared to both controls and AD/CAA groups (lower
panel).

138

reduced synaptic copper, these observations cannot establish a causal link between
dynactin and copper trafficking. To accomplish this, we will knock down p62 expression
in a neuronal cell culture system and determine whether the previous findings of
decreased synaptic and increased axonal copper can be reproduced. If successful, these
studies would establish the necessary causal link.
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CHAPTER 7
DISCUSSION AND CONCLUSIONS
Several studies conducted by our group demonstrated that iron was not increased
in Alzheimer’s disease brain by multiple modalities, contrary to a widely accepted belief
in the field (Magaki 2007, Kirsch 2009). Additionally, key iron regulatory proteins
including IRPs were shown to be unchanged in Alzheimer’s disease and a systematic
microchip analysis of the expression of iron metabolism-related genes failed to identify
even a single gene altered by +/- 2 fold compared to age-matched normal brain (Magaki
2007 and unpublished observations). These findings are in stark contrast to most reports
in the field which seem to indicate that iron levels and the associated homeostatic
pathways are severely dysregulated in AD and forced us to re-evaluate the hypotheses
behind our studies (Bush 2000, Rottkamp 2001).
These observations led us to several important and fundamental questions. First,
because the notion that iron is increased in Alzheimer’s disease is entrenched and central
to a major hypothesis regarding the etiology of the disease and multiple clinical trials, it
was important to resolve whether or not iron is truly dysregulated in Alzheimer’s disease
in a definitive way. Second, if iron is not generally dysregulated, it is reasonable to ask if
perhaps the notion that it is dysregulated developed from a subset of patients in whom
brain iron is increased. Therefore, identifying what subset of patients have altered metal
levels and ultimately what mechanism(s) leads to alterations in transition metal handling
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in the brains of Alzheimer’s disease patients is the second major objective of these
studies.
Through meta-analysis, we found that iron levels are not altered in Alzheimer’s
disease. We determined the tissue fixation depletes brain iron levels and this effect is
greater in normal brain than in AD brain – this effect no doubt contributed in part to the
misconception that brain iron is increased in AD as a substantial portion of that literature
studied fixed tissues (Schrag 2010). Additionally, we found that all studies which
quantitatively demonstrated increased iron in brain from AD patients were conducted at
the same laboratory (Lovell 1997, Deibel 1996, Thompson 1988, Ehmann 1986,
Wenstrup 1992, Cornett 1995). Seven independent laboratories found that iron was not
increased in AD neocortex (Andrasi 2000, Corrigan 1991, Griffiths 1993, House 2007,
Panayi 2002, Magaki 2007, Plantin 1987, Religa 2006, Stedman 1997, Ward and Mason
1987). Never-the-less, studies showing increased iron were cited more than 5 times as
often as those showing no increase, and this effect was particularly strong among
narrative review articles (ISI, Science Citation Index).
To answer the second question, we stratified Alzheimer’s disease patients by the
degree of vascular involvement in the neuropathology. Patients with severe CAA were
place in one group, those with only parenchymal features were grouped in another and
age-matched controls were the third group. When all AD patients were analyzed
together, as expected no significant changes in iron levels were detected, but when CAApredominant cases were analyzed separately they were found to have significantly more
iron than both controls and AD patients with only parenchymal pathology. Additionally,
heme degradation enzymes heme oxygenase 1 and biliverdin reductase B were increased
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in the CAA group. These observations argue that pathologic iron deposition is a result of
microbleeding associated with CAA and may account for the numerous qualitative
reports of increased iron in AD.
We also felt it was necessary to identify potential mechanisms underlying the
vascular fragility associated with CAA. We determined that both ferrous iron and
monovalent copper prominently deposited on arterioles affected by amyloid deposition –
these are both highly reactive oxidative species prone to participation in Fenton reactions
which could undermine the stability of the vessels. Moreover, we identified foci of
hypointensity in post-mortem MR imaging using susceptibility weight sequences of brain
tissue from patients who were pathologically confirmed to suffer from severe CAA
(Schrag 2010). We confirmed that these hypointensities represented microhemorrhagic
events and were then able to observe in detail the pathology that is associated with
microvascular bleeding. Consistent with previous observations, heme oxygenase-1 was
found to be remarkably increased in the penumbral region about a microhemorrhage and
cellular apoptosis was significantly increased in this region. Extravasated blood products
were found to propagate along the local vascular elements propagating an inflammatory
response regionally that may damage the microvasculature. One additional finding is
particularly interesting, late complement component C6 (indicative of a lytic process)
was heavily deposited on grey matter arterioles, although early complement (while
present in parenchyma) could not be detected on vascular elements. This finding led us
to believe that complement may be involved in beta-amyloid clearance from the
parenchyma.
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Finally, in the course of these studies, we became aware of a defect in copper
transport and metabolism. In patients with severe parenchymal pathology without CAA,
copper in synaptic vesicles was found to be significantly reduced compared to
Alzheimer’s disease patients with vascular involvement. Additionally, monovalent
copper in this group of subjects was distributed differently – accumulation of copper in
the axons and cell bodies was noted whereas monovalent copper was limited to a
perinuclear distribution in both of the other cases. This led us to review proteomic data
generated from serum collected from patients with Alzheimer’s disease to attempt to
identify evidence of abnormal protein fragments in peripheral blood that were associated
with axonal transport. A subunit of dynactin (dynein activating complex), p62, was
found in serum of patients with Alzheimer’s disease without CAA. It was undetectable
in all control cases and was only detected in one CAA case. We subsequently determined
that p62 levels in brain are depleted in the AD-only group compared to both AD / CAA
and control groups. It will be necessary to demonstrate that alterations in dynactin levels
and copper in synaptic vesicles are linked. To evaluate this, we will determine whether
silencing p62 expression in vitro in neuronal culture causes similar depletion of copper
from synaptic vesicles and accumulation of copper in axon processes.
Cumulatively, these studies have resolved a number of longstanding questions in
the field of Alzheimer’s disease research. Most significantly, we have shown that the
notion that iron levels are increased in Alzheimer’s disease is a misconception – one that
may have resulted in tens of millions of misdirected research dollars and has put patients
at risk in clinical trials. Additionally, we worked on developing two biomarkers, one an
MRI based finding that previously lacked adequate pathological confirmation and one a
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new biochemical marker in plasma of altered copper metabolism and axonal transport.
Finally, we have begun to show that AD without CAA and AD with CAA are
biochemically quite different, and perhaps should not be approached therapeutically in
the same ways. These findings have led to a new focus in our continuing work. In
particular, we are working on dissecting copper metabolism and its relationship to AD.
Nearly all of the major protein players in AD have copper binding sites and significant
abnormalities of copper handling have already been identified. Clarifying the role of this
metal in AD may reveal new targets for therapy. And finally, we will continue to work
toward understanding the mechanism of vascular weakening in CAA. This work is
promising because significant abnormalities in complement activation may treatable. A
novel inhibitor of late complement was recently approved for clinical use in paroxysmal
nocturnal hemoglobinuria. When we better understand the role of complement in the
clearance of beta-amyloid from the brain and in the degeneration of the cerebral
microvasculature, therapeutic application of this or other inhibitors of complement may
be appropriate.
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